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1 .INTRODUCTION 
 
 Gastro retentive Drug Delivery System 
Since the last three decades many drug molecules formulated as Gastro Retentive 
Drug Delivery System (GRDDS) have been patented keeping in view its commercial success.  
The bioavailability of drugs with an absorption window in the upper part of the GIT (gastro 
intestinal tract) is generally limited with conventional pharmaceutical dosage forms. These 
drugs can be delivered ideally by slow release from the stomach to give a localized effect at 
the site of action. Improved efficacy is expected for drugs that are used in the treatment of 
gastric disorders like ulcers and bacterial infections (H.pylori that resides in the antral region 
of stomach behind the mucosal layer). Many drugs categorized as once-a-day delivery have 
been demonstrated to have suboptimal absorption due to dependence on the transit time of the 
dosage form, making traditional extended release development challenging. Therefore, a 
system designed for longer gastric retention will extend the time within which drug 
absorption can occur1.  
Gastric emptying of dosage forms is an extremely variable process and ability to 
prolong and control the emptying time is a valuable asset for dosage forms, which reside in 
the stomach for a longer period of time than conventional dosage forms. Several difficulties 
are faced in designing sustained release systems for better absorption and enhanced 
bioavailability.  
The residence time of conventional sustained release dosage forms and, thus, of their 
drug release into the stomach and upper intestine is often short. To overcome this restriction 
and to increase the bioavailability of these drugs, sustained drug delivery systems, with a 
prolonged residence time in the stomach, can be used. 
Gastro-retentive dosage forms (GRDFs) are designed to be retained in the stomach for 
a prolonged time and release their active ingredients and thereby enable sustained and 
prolonged input of the drug to the upper part of the gastrointestinal (GI) tract. This 
technology has generated enormous attention over the last few decades owing to its potential 
application to improve the oral delivery of some important drugs, for which prolonged 
retention in the upper GI tract can greatly improve their oral bioavailability and/or their 
therapeutic outcome  
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 Suitable Drug Candidates for Gastro retention2 
Various drugs have their greatest therapeutic effect when released in the stomach, 
particularly when the release is prolonged in a continuous, controlled manner. Drugs 
delivered in this manner have a lower level of side effects and provide their therapeutic 
effects without the need for repeated dosages or with a low dosage frequency 
 Drugs with narrow absorption window in GI tract, e.g., riboflavin and levodopa 
 Drugs which are primarily absorbed from stomach and upper part of GIT e.g., calcium 
supplements, chlordiazepoxide and cinnarazine 
 Drugs that act locally in the stomach, e.g., antacids and misoprostol 
 Drugs that degrade in the colon, e.g., ranitidine HCl and metronidazole 
 Drugs that disturb normal colonic bacteria, or degrade in the colon e.g: Amoxicillin 
trihydrate 
 Poorly soluble at an alkaline pH 
 Particularly useful for the treatment of peptic ulcers caused by H. Pylori Infections 
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FLOATING DRUG DELIVERYSYSTEM 
 
    Oral drug delivery is the most widely utilized route of administration among all the  
routes that have been explored for systemic delivery of drugs via pharmaceutical products of 
different dosage form. Oral route is considered most natural, uncomplicated, convenient and 
safe due to its ease of administration, patient acceptance and cost-effective manufacturing 
process1 
 Pharmaceutical products designed for oral delivery are mainly conventional drug 
delivery systems, which are designed for immediate release of drug for rapid absorption. 
These immediate release dosage forms have some limitations such as2, 3: 
 Drugs with short half-life require frequent administration, which increase the 
chances of missing dose of drug leading to poor patient compliance 
 A typical peak-valley plasma concentration-time profile is obtained which makes 
it difficult to attainment of steady state condition 
 The unavoidable fluctuations in the drug concentration may lead to under 
medication or overmedication as the CSS values fall or rise beyond the therapeutic 
range 
 The fluctuating drug levels may lead to precipitation of adverse effects especially 
of a drug with small therapeutic index, whenever overmedication occurs 
In order to overcome the drawbacks of conventional drug deliver systems, several 
technical advancements have led to the development of controlled drug delivery system that 
could revolutionize method of medication and provide a number of therapeutic benefits4.  
Controlled Drug Delivery Systems: 
 Controlled drug delivery systems have been developed which are capable of 
controlling the rate of drug delivery, sustaining the duration of therapeutic activity and/or 
targeting the delivery of drug to a tissue5.  
 Controlled drug delivery or modified drug delivery systems are conveniently divided  
into four categories. 
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i. Delayed release  
ii. Sustained release  
iii. Site-specific targeting 
iv. Receptor targeting  
More precisely, Controlled delivery can be defined as: - 
1) Sustained drug action at a predetermined rate by maintaining a relatively constant, 
effective drug level in the body with concomitant minimization of undesirable side 
effects. 
2) Localized drug action by spatial placement of a controlled release system adjacent to 
or in the diseased tissue.  
3) Targeted drug action by using carriers or chemical derivatives to deliver drug to a 
particular target cell type.  
4) Provide a physiologically/therapeutically based drug release system. In other words, 
the amount and the rate of drug release are determined by the physiological/ 
therapeutic needs of the body.  
 A controlled drug delivery system is usually designed to deliver the drug at particular 
rate. Safe and effective blood levels are maintained for a period as long as the system 
continues to deliver the drug. Controlled drug delivery usually results in substantially 
constant blood levels of the active ingredient as compared to the uncontrolled fluctuations 
observed when multiple doses of quick releasing conventional dosage forms are administered 
to a patient.  
Advantages of Controlled Drug Delivery System:  
1. Avoid patient compliance problems.  
2. Dosage frequency were reduced  
a) Minimize or eliminate local side effects 
b) Minimize or eliminate systemic side effects  
c) Obtain less potentiation or reduction in drug activity with chronic use. 
d) Minimize drug accumulation with chronic dosing.  
3. Improve efficiency in treatment  
a) Cures or controls condition more promptly. 
b) Improves control of condition i.e., reduced fluctuation in drug level. 
c) Improves bioavailability of some drugs. 
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d) Make use of special effects, eg. Sustained-release aspirin for morning relief of 
arthritis by dosing before bedtime.  
4. Economy i.e. reduction in health care costs. The average cost of treatment over an 
extended time period may be less, with less frequency of dosing, enhanced therapeutic 
benefits and reduced side effects. The time required for health care personnel to dispense 
and administer the drug and monitor patient is also reduced 
Disadvantages: 
1) Decreased systemic availability in comparison to conventional dosage forms, which 
may be due to incomplete release, increased first-pass metabolism, increased 
instability, insufficient residence time for complete release, site specific absorption, 
pH dependent stability etc.  
2) Poor in vitro – in vivo correlation.  
3) Possibility of dose dumping due to food, physiologic or formulation variables or 
chewing or grinding of oral formulations by the patient and thus, increased risk of 
toxicity.  
4) Retrievals of drug are difficult in case of toxicity, poisoning or hypersensitivity 
reactions.  
5) Reduced potential for dosage adjustment of drugs normally administered in varying 
strengths.  
  Oral Controlled Drug Delivery Systems6,7 
 Oral controlled release drug delivery is a drug delivery system that provides the continuous 
oral delivery of drugs at predictable and reproducible kinetics for a predetermined period 
throughout the course of GI transit and also the system that target the delivery of a drug to a 
specific region within the GI tract for either local or systemic action.  
 All the pharmaceutical products formulated for systemic delivery via the oral route of 
administration, irrespective of the mode of delivery (immediate, sustained or controlled 
release) and the design of dosage form (solid dispersion or liquid), must be developed within 
the intrinsic characteristics of GI physiology. Therefore the scientific framework required for 
the successful development of oral drug delivery systems consists of basic understanding of 
(i) Physicochemical, pharmacokinetic and pharmacodynamic characteristics of the drug (ii) 
the anatomic and physiologic characteristics of the gastrointestinal tract and (iii) 
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physicochemical characteristics and the drug delivery mode of the dosage form to be 
designed.  
The main areas of potential challenge in the development of oral controlled drug delivery 
systems are 
 Development of a drug delivery system: To develop a viable oral controlled release 
drug delivery system capable of delivering a drug at a therapeutically effective rate to 
a desirable site for duration required for optimal treatment 
 Modulation of gastrointestinal transit time: To modulate the GI transit time so that the 
drug delivery system developed can be transported to a target site or to the vicinity of 
an absorption site and reside there for a prolonged period of time to maximize the 
delivery of a drug dose 
 Minimization of hepatic first pass elimination: If the drug to be delivered is subjected 
to extensive hepatic first-pass elimination, preventive measures should be devised to 
either bypass or minimize the extent of hepatic metabolic effect 
 Conventional oral controlled dosage forms suffer from mainly two adversities8. The 
short gastric retention time (GRT) and unpredictable gastric emptying time (GET). A 
relatively brief GI transit time of most drug products impedes the formulation of single 
daily dosage forms.  
 Altering the gastric emptying can overwhelm these problems. Therefore it is 
desirable, to formulate a controlled release dosage form that gives an extended GI 
residence time. 
  Extended release dosage form with prolonged residence time in stomach are 
highly desirable for drugs.  
i. That are locally active in stomach,  
ii. That have an absorption window in the stomach or in the upper small intestine,  
iii. That are unstable in the intestinal or colonic environment,  
iv. Have low solubility at high pH values. 
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Gastro retentive Dosage Form (GRDF):9,10 
 It is evident from the recent scientific and patient literature that an increased interest  
in novel dosage forms that are retained in stomach for a prolonged and predictable period of  
time exists today in academic and industrial research groups. One of the most 
feasibleapproaches for achieving a prolonged and predictable drug delivery in the GI tract is 
to control the gastric residence time (GRT), i.e. gastro retentive dosage form (GRDFs or 
GRDS).  
 GRDFs extend significantly the period of time over which the drugs may be released. 
They not only prolong dosing intervals, but also increase patient compliance beyond the level 
of existing controlled release dosage form.  
 Dosage form with prolonged GRT, i.e. gastro retentive dosage form (GRDF), 
willbring about new and important therapeutic options such as: 
 
1) This application is especially effective in sparingly soluble and insoluble drugs. It is 
known that, as the solubility of a drug decreases, the time available for drug 
dissolution becomes less adequate and thus the transit time becomes a significant 
factor affecting drug absorption. To override this problem, erodible, gastro retentive 
dosage forms have been developed that provide continuous, controlled administration 
of sparingly soluble drugs at the absorption site11.  
2) GRDFs greatly improve the pharmacotherapy of the stomach through local drug 
release, leading to high drug concentration at the gastric mucosa. (For e.g. Eradicating 
Helicobacter pylori from the sub mucosal tissue of stomach) making it possible to 
treat stomach and duodenal ulcers, gastritis and oesophagitis, reduce the risk of 
gastric carcinoma and administer non-systemic controlled release antacid 
formulations (calcium carbonate).  
3) GRDFs can be used as carriers for drugs with so-called absorption windows. These 
substances for e.g. antiviral, antifungal and antibiotic agents (Sulphonamides, 
Quinolones, Penicillin’s, Cephalosporin’s, amino glycosides, Tetracycline’s etc.) are 
taken up only from very specific sites of the GI mucosa.  
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BIOLOGICAL ASPECTS OF GRDFs:12 
Role of GI tract: 
Stomach  
 The stomach is J-shaped organ located in the upper left hand portion of the abdomen, 
just below the diaphragm. It occupies a portion of the epigastric and left hydrochondriac 
region. The main function of the stomach is to store the food temporarily, grind it and then 
release it slowly into the duodenum. Due to its small surface area very little absorption takes 
place from the stomach. It provides barrier to the delivery of drugs to small intestine. 
 
 
Fig1: Anatomy of Stomach 
 
 Physiology of stomach: 
The stomach is divided into three anatomical regions. I) Fundus ii) Body and iii) 
Pylorus (or antrum). The proximal stomach consisted of fundus and body, which serves as a 
reservoir for ingested materials, whereas the distal region (pylorus) is the major site of 
mixing motions, acting as a pump to propel gastric contents for gastric emptying. Gastric 
emptying occurs both in fasting as well as fed states13. 
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The GI tract is always in a state of continuous motility. There are two modes of 
motility pattern. The digestive mode and interdigestive mode. In case of fasted state an 
interdigestive series of electrical events occurs in cyclic manner both through stomach and 
small intestine every 2-3 hr. This electrical activity is termed as interdigestive my electric 
cycle. 
 
  
 
 
 
 
PHASE I:  
The quiescent period, lasts from 30 to 60 minutes and is characterized by a lack of 
secretary, electrical and contractile activity. 
PHASE II: 
Exhibits intermittent activity for 20-40 min, during which the contractile motions 
increase in frequency and size. Bile enters the duodenum during this phase, whereas gastric 
mucus discharge occurs during the latter part of phase II and throughout phase III. 
Phase III: 
Has a housekeeping role and serves to clear all indigestible materials from the 
stomach and small intestine. Consequently, a controlled-release gastrointestinal drug delivery 
system must be capable of resisting the house keeping action of phase III. Studies revealed 
that in the fed state, the gastric emptying rate is slowed since the onset of MMC is delayed. It 
can be concluded that feeding results in a lag time before onset of gastric emptying cycle14, 15.  
PHASE IV:  
Is the transition period of 0-5 minutes between Phase III &I. 
 
 
 
 
 Phase I : Period of no contraction. 
Phase II : Period of intermittent contraction.  
Phase III : Period of regular contractions at the maximal frequency that 
migrate distally. 
Phase IV : Period of transition between phase III and phase I. 
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Fig 2-:  Interdigestivemyloelectriccycle 
 
REQUIREMENTS FOR GASTRO RETENTION 16 
From the discussion of the physiological factors in stomach, to achieve gastro 
retention, the dosage form must satisfy some requirements. One of the key issues is that the 
dosage form must be able to withstand the forces caused by peristaltic waves in the stomach 
and constant grinding and churning mechanisms. It must resist premature gastric emptying 
and once the purpose has been served, it should be removed from the stomach with ease. 
 
APPROACHES TO GASTRIC RETENTION 17,18 
Various approaches have been pursued to increase the retention of an oral dosage 
form in the stomach. These systems include: Floating systems,Bio adhesive systems, swelling 
and expanding systems, High density systems, Modified systems   
    
 
 
 
 
 
Fig 3 Classification of gastro retentive drug delivery system 
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Buoyant/ Floating Systems: 
Floating Drug Delivery Systems 19 (FDDS) have a bulk density lower than gastric 
fluids and thus remain buoyant in the stomach for a prolonged period of time, without 
affecting the gastric emptying rate. While the system is floating on the gastric contents, the 
drug is released slowly at a desired rate from the system. After the release of the drug, the 
residual system is emptied from the stomach. This results in an increase in the GRT and a 
better control of fluctuations in the plasma drug concentrations. Floating systems can be 
classified into two distinct categories, non-effervescent and effervescent systems. 
 
 
                                      Fig 4: Mechanism of floating system 
 
Bio/Muco-adhesive Systems:17 
Bio/muco-adhesive systems are those which bind to the gastric epithelial cell surface 
or mucin and serve as a potential means of extending the GRT of drug delivery system in the 
stomach, by increasing the intimacy and duration of contact of drug with the biological 
membrane.  
The surface epithelial adhesive properties of mucin have been well recognized and 
applied to the development of GRDDS based on bio/muco-adhesive polymers. The ability to 
provide adhesion of a drug (or a delivery system) to the GI wall provides a longer residence 
time in a particular organ site, thereby producing an improved effect in terms of local action 
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or systemic effect. Binding of polymers to the mucin/epithelial surface can be divided into 
three broad categories: – 
1. Hydration-mediated adhesion. 
2. Bonding-mediated adhesion. 
3. Receptor-mediated adhesion. 
Swelling and Expanding Systems:18 
These are the dosage forms, which after swallowing; swell to an extent that prevents 
their exit from the pylorus. As a result, the dosage form is retained in the stomach for a long 
period of time. These systems may be named as “plug type system”, since they exhibit the 
tendency to remain logged at the pyloric sphincter if that exceed a diameter of approximately 
12-18 mm in their expanded state. The formulation is designed for gastric retention and 
controlled delivery of the drug into the gastric cavity. Such polymeric matrices remain in 
thegastric cavity for several hours even in the fed state.A balance between the extent and 
duration of swelling is maintained by the degree of cross-linking between the polymeric 
chains. A high degree of cross-linking retards the swelling ability of the system maintaining 
its physical integrity for prolonged period. 
High Density Systems:20 
These systems with a density of about 3 g/cm3 are retained in the rugae of the stomach and 
are capable of withstanding its peristaltic movements. A density of 2.6-2.8 g/cm3 acts as a 
threshold value after which such systems can be retained in the lower part of the stomach. 
High-density formulations include coated pellets. Coating is done by heavy inert material 
such as barium sulphate, zinc oxide, titanium dioxide, iron powder etc. They are retained in 
the antrum of stomach. 
Incorporation of Passage Delaying Food Agents: 
Food excipients like fatty acids e.g. salts of myristic acid change and modify the 
pattern of the stomach to a fed state, thereby decreasing gastric emptying rate and permitting 
considerable prolongation of release. The delay in the gastric emptying after meals rich in 
fats is largely caused by saturated fatty acids with chain length of C10-C14. 
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Ion Exchange Resins21: 
A coated ion exchange resin bead formulation has been shown to have gastric 
retentive properties, which was loaded with bicarbonates. Ion exchange resins are loaded with 
bicarbonate and a negatively charged drug is bound to the resin. The resultant beads were 
then encapsulated in a semi-permeable membrane to overcome the rapid loss of carbon 
dioxide. Upon arrival in the acidic environment of the stomach, an exchange of chloride and 
bicarbonate ions take place. As a result of this reaction carbon dioxide was released and 
trapped in the membrane thereby carrying beads towards the top of gastric content and 
producing a floating layer of resin beads in contrast to the uncoated beads, which will sink 
quickly. 
Osmotic Regulated Systems22: 
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a bio erodible capsule. In the stomach the capsule quickly 
disintegrates to release the intragastricosmotically controlled drug delivery device. The 
inflatable support inside forms a deformable hollow polymeric bag that contains a liquid that 
gasifies at body temperature to inflate the bag. The osmotic controlled drug delivery device 
consists of two components – drug reservoir compartment and osmotically active 
compartment. 
TYPES   OF   FLOATING   DRUG   DELIVERY   SYSTEMS (FDDS)23-25 
 Based on the mechanism of buoyancy, two distinctly different technologies have been 
utilized in development of FDDS which are: 
A. Effervescent System, and 
B. Non- Effervescent System. 
EFFERVESCENT SYSTEM:- 
Effervescent systems include use of gas generating agents, carbonates (ex. Sodium 
bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present in the 
formulation to produce carbon dioxide (CO2) gas, thus reducing the density of the system and 
making it float on the gastric fluid. An alternative is the incorporation of matrix containing 
portion of liquid, which produce gas that evaporates at body temperature26. 
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These effervescent systems further classified into two types. 
I. Gas Generating systems  
II. Volatile Liquid/Vacuum Containing Systems. 
Gas – Generating Systems: 
 
Intra Gastric Single Layer Floating Tablets or Hydro dynamically Balanced System 
(HBS): 
 These are formulated by intimately mixing the CO2 generating agents and the drug 
within the matrix tablet.   These have a bulk density lower than gastric fluids and therefore 
remain floating in the stomach unflattering the gastric emptying rate for a prolonged period. 
The drug is slowly released at a desired rate from the floating system and after the complete 
release the residual system is expelled from the stomach. This leads to an increase in the GRT 
and a better control over fluctuations in plasma drug concentration.  
   These are also compressed tablets containing two layers i.e., 
i. Immediate release layer and  
ii. Sustained release layer.                   
Multiple Unit type floating pills: 
 These systems consist of sustained release pills as ‘seeds’ surrounded by double 
layers. The inner layers consist of effervescent agents while the outer layer is of swellable 
membrane layer. When the system is immersed in dissolution medium at body temperature, it 
sinks at once and then forms swollen pills like balloons, which float as they have lower 
density. This lower density is due to generation and entrapment of CO2 within the system.  
Volatile Liquid / Vacuum Containing Systems: 
Intragastric Floating Gastrointestinal Drug Delivery System:These systems can be made 
to float in the stomach because of floatation chamber, which may be a vacuum or filled with 
air or a harmless gas, while drug reservoir is encapsulated inside a micro porous 
compartment.   
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Inflatable Gastrointestinal Delivery Systems: 
In these systems an inflatable chamber is incorporated, which contains liquid ether 
that gasifies at body temperature to cause the chamber to inflate in the stomach. These 
systems are fabricated by loading the inflatable chamber with a drug reservoir, which can be 
a drug, impregnated polymeric matrix, then encapsulated in a gelatin capsule.  
After oral administration, the capsule dissolves to release the drug reservoir together with the 
inflatable chamber. The inflatable chamber automatically inflates and retains the drug 
reservoir compartment in the stomach. The drug continuously released from the reservoir into 
the gastric fluid27.  
IntragastricOsmotically Controlled Drug Delivery System:   
 It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach, the capsule quickly 
disintegrates to release the intragastircosmotically controlled drug delivery device. The 
inflatable support inside forms a deformable hollow polymeric bag that contains a liquid that 
gasifies at body temperature to inflate the bag. The osmotic pressure controlled drug delivery 
device consists of two components; drug reservoir compartment and an osmotically active 
compartment28.  
  The drug reservoir compartment is enclosed by a pressure responsive 
collapsible bag, which is impermeable to vapour and liquid and has a drug delivery orifice. 
The osmotically active compartment contains an osmotically active salt and is enclosed 
within a semi permeable housing. In the stomach, the water in the GI fluid is continuously 
absorbed through the semi permeable membrane into osmotically active compartment to 
dissolve the osmotically active salt. An osmotic pressure is thus created which acts on the 
collapsible bag and in turn forces the drug reservoir compartment to reduce its volume and 
activate the drug reservoir compartment to reduce its volume and activate the drug release of 
a drug solution formulation through the delivery orifice. The floating support is also made to 
contain a bioerodible plug that erodes after a predetermined time to deflate the support. The 
deflated drug delivery system is then emptied from the stomach.10 
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NON-EFFERVESCENT SYSTEMS:7 
 The Non-effervescent FDDS based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non-
effervescent FDDS are gel forming or highly swellable cellulose type hydrocolloids, 
polysaccharides and matrix forming material such as Polycarbonate, Polyacrylate, 
Polymethacrylate, polystyrene as well as bioadhesive polymer such as Chitosan and 
Carbopol. The various types of this system are as: 
Single Layer Floating Tablets: 
 They are formulated by intimate mixing of drug with a gel-forming hydrocolloid, 
which swells in contact with gastric fluid and maintain bulk density of less than unity. The air 
trapped by the swollen polymer confers buoyancy to these dosage forms.  
Bilayer Floating Tablets:  
A bilayer tablet contain two layer one immediate release layer which release initial 
dose from system while the another sustained release layer absorbs gastric fluid, forming an 
impermeable colloidal gel barrier on its surface, and maintain a bulk density of less than unity 
and thereby it remains buoyant in the stomach.    
Alginate Beads: 
Multi unit floating dosage forms were developed from freeze-dried calcium alginate. 
Spherical beads of approximately 2.5 mm diameter can be prepared by dropping a sodium 
alginate solution into aqueous solution of calcium chloride, causing precipitation of calcium 
alginate leading to formation of porous system, which can maintain a floating force for over 
12 hours.  
Hollow Microspheres: 
Hollow microspheres (micro balloons), loaded with drug in their outer polymer shells 
were prepared by a novel emulsion-solvent diffusion method. The ethanol: dichloromethane 
solution of the drug and an enteric acrylic polymer was poured into an agitated aqueous 
solution of PVA that was thermally controlled at 400C. The gas phase generated in dispersed 
polymer droplet by evaporation of dichloromethane formed an internal cavity in microsphere 
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of polymer with drug. The micro balloons floated continuously over the surface of acidic 
dissolution media containing surfactant for more than 12 hours in vitro.29 
Factors Controlling Gastric Retention Time of Dosage Form: 10,13 
 The gastric retention time (GRT) of dosage form is controlled by several factors that 
affect their efficacy as a gastroretentive system.  
 Density of dosage form:  – the density of gastric fluid is reported to be 
1.004g/cm3.the density of the dosage from should be less than this for buoyancy, so 
that it is retained in stomach for longer period of time. The dosage from may be 
having a high density in the beginning, but due to reduction in density by swelling it 
will float in stomach 
 Size of the dosage from: –studies on the effect of particle size on gastric retention 
have been inconclusive. In general it is know that indigestive solids larger than 1-
2mm are retained in stomach throughout the post-prandial period, after which they are 
emptied in stomach throughout the post-prandial period, after which they are emptied 
by cyclically recurring burst of interdigestive gastric contractions. However studies 
have suggested that this observation cannot be generalized. Many recent studies have 
shown that non-disintegrating tablets as large as 7mm can be emptied from human 
stomach during the post-prandial period, while 13mm tablets are retained until arrival 
of subsequent sweeping “housekeeper wave”. This emphasizes the need for size 
enlargement of DF in stomach in order to prolong GRT30 
 Shape of dosage form – Tetrahedron and ring-shaped devices with a flexural 
modulus of 48 and 22.5 kilo pounds per square inch (KPSI) are reported to have better 
GRT. 90% to 100% retention at 24 hours compared with other shapes 
 Single or multiple unit formulation – Multiple unit formulations show a more 
predictable release profile and insignificant impairing of performance due to failure of 
units, allow co-administration of units with different release profiles or containing 
incompatible substances and permit a larger margin of safety against dosage form 
failure compared with single unit dosage forms 
 Fed or unfed state – Under fasting conditions, the GI motility is characterized by 
periods of strong motor activity or the migrating myoelectric complex (MMC) that 
occurs every 1.5 to 2 hours. The MMC sweeps undigested material from the stomach 
and, if the timing of administration of the formulation coincides with that of the 
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MMC, the GRT of the unit can be expected to be very short. However, in the fed 
state, MMC is delayed and GRT is considerably longer.31 
 Nature of meal – Feeding of indigestible polymers or fatty acid salts can change the 
motility pattern of the stomach to a fed state, thus decreasing the gastric emptying rate 
and prolonging drug release 
 Caloric content – GRT can be increased by four to 10 hours with a meal that is high 
in proteins and fats 
 Frequency of feed – The GRT can increase by over 400 minutes when successive 
meals are given compared with a single meal due to the low frequency of MMC 
 Gender – Mean ambulatory GRT in males (3.40.6 hours) is less compared with their 
age and race-matched female counterparts (4.61.2 hours), regardless of the weight, 
height and body surface32 
 Age – Elderly people, especially those over 70, have a significantly longer GRT 
 Posture – GRT can vary between supine and upright ambulatory states of the patient. 
Concomitant drug administration – Anticholinergics like Atropine and Propantheline, 
opiates like Codeine and prokinetic agents like Metoclopramide and Cisapride33 
 
Advantages of FDDS:34,35 
Floating dosage systems form important technological drug delivery systems with gastric 
retentive behavior and offer several advantages in drug delivery. These advantages 
include:  
 Improved drug absorption, because of increased GRT and more time spent by the 
dosage form at its absorption site 
 Controlled delivery of drugs 
 Delivery of drugs for local action in the stomach 
 Minimizing the mucosal irritation due to drugs, by drug releasing slowly at   
controlled rate 
 Treatment of gastrointestinal disorders such as gastro-esophageal reflux 
 Simple and conventional equipment for manufacture 
 Ease of administration and better patient compliance 
 Site-specific drug delivery 
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Disadvantages of FDDS:36 
 Gastric retention is influenced by many factors such as gastric motility, pH and 
presence of food. These factors are never constant and hence the buoyancy cannot be 
predicted 
 Drugs that cause irritation and lesion to gastric mucosa are not suitable to be 
formulated as floating drug delivery systems 
 High variability in gastric emptying time due to its all or non-emptying process 
 Gastric emptying of floating forms in supine subjects may occur at random and 
becomes highly dependent on the diametral size. Therefore patients should not be 
dosed with floating forms just before going to bed 
List of Drugs - Floatable Drug Delivery Systems:37 
S. No. DOSAGE FORM DRUGS 
1 Microspheres Aspirin, Grisiofulvin, p-nitroanilline, Ibuprofen, 
Terfinadine, Tranilast. 
2 Granules Diclofenac sodium, Indomethacin, Predmisolone 
3 Films Cinnarizine 
4 Powders Several basic drugs 
5 Capsules ChlordiazepoxideHCl, Diazepam, Furosemide, L-
Dopa, benserazide, Misoprostol, Propranolol HCl, 
Ursodeoxycholic acid 
6 Tablets/pills Acetaminophen, Acetylsalicylic acid, Amoxicillin 
trihydrate, Ampicillin, Atenolol, Chlorpheniramine, 
Cinnazirine, Diltiazem, Fluorouracil, 
Isosorbidemononitrate, Isosorbidedinitrate, p-
aminobenzoic acid, Piretanide, Prednisolone, 
Quinidine gluconate, Riboflavin-5-phosphate, 
Sotalol, Theophylline, Verapamil HCl 
20 
 
 
Marketed Products of FDDS: 10\ 
 
 
 
 
 
S. 
NO. 
BRAND 
NAME 
DRUG 
(DOSE) 
COMPANY, 
COUNTRY 
REMARKS 
1. Modapar® Levodopa 
(100 mg), 
Benserazide 
(25 mg) 
RocheProducts, USA Floating CR capsule 
2. Valrelease® Diazepam (15 
mg) 
Hoffmann-LaRoche, 
USA 
Floating capsule 
3. Liquid 
Gavison® 
Al hydroxide 
(95 mg), Mg 
carbonate 
(358 mg) 
GlaxoSmith Kline, India Effervescent floating 
liquid alginate 
preparation 
4. Topalkan® Al-Mg 
antacid 
Pierre Fabre Drug, 
France 
Floating liquid 
alginate preparation 
5. Conviron Ferrous 
sulphate 
Ranbaxy, India Colloidalgel forming 
FDDS 
6. Cifran OD® Ciprofloxacin 
(1 gm) 
Ranbaxy, India Gas-generating 
floating tablet 
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2. LITERATURE REVIEW 
 
Mohammad   Shahidul   Islam  et al.,38The purpose of this work is to determine the in-vitro 
release kinetic of Ciprofloxacin Hcl sustained release dosage form using HPMC K15M, 
HPMC K4M and HPMC K4M premium polymers. From this studies they concluded that at 
least 6% HPMC K15M CR showed desired sustained release and at least15% HPMC K4M 
and 6.7%HPMC K4M premium met the desire sustained action. It proved that HPMC K15M 
was better than HPMC K4M CR and HPMC K4M premium for Ciprofloxacin Hcl sustained 
release matrix tablets by direct compression. 
A.Badoni et al.,39Stated that GRDDS offers various potential advantages for a drug with poor 
bioavailability. Drug absorption in gastro intestinal tract is highly variable process and 
prolong gastric retention time of dosage form extends the time for drug absorption. Different 
approaches of GRDDS are studied each having their own advantages and disadvantages .In 
future it can early assumed that GRDDS will become more popular in terms of developing 
drugs to systemic circulation with improving efficiency of various types of pharmacotherapy. 
KrishnarajanDevarajan  et al.,40 Assessed that hydro dynamicaly balanced tablets of 
Ciprofloxacin Hcl can be formulated with an approach to increase gastric residence and 
thereby increase the drug bioavailability. An attempt to develope floating tablets of 
ciprofloxacin Hcl using Sodium bicarbonate as gas generating agent and HPMC (K100M, 
K4M,E50M) as hydrophilic polymer by direct compression. The formulated tablets showed 
compliance for physical and chemical parameters and the result of stability studies indicates 
that the most suitable storage condition and temperature for Ciprofloxacin floating tablets 
was 2-8 C for a period of 60days. 
Ajay Bagherwal  et al.,41Concluded that increase in the proportion of polymer (HPMC K4M 
andCarbopol 934 was associated with decrease in overall cumulative drug release rate. 
Release of formulation batch with carbopol 12% was found to maximum release at the end 
of6hours.Therelease from the system was found to concentration independent and matrix 
diffusion mediated. The tablets was found t have excellent physical characters. 
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K.Ravishankar et al.,42 Prepare Ciprofloxacin bioadhesive and floating tablets to increase 
the gastric residence time and as well as bioavailability thereby it increases patient 
compliance. These floating tablets prepared by using polymers like HPMC K4M and 
carbopol .Sodium bicarbonate with combination of citric acid are used as gas generating 
agents. 
Upendarrao.Galla et al.,43Stated that the principle of hydro dynamically balanced controlled 
drug delivery system offers a suitable and practical approach to obtained controlled release of 
Ciprofloxacin with enhance bioavailability and reduce the dosing frequency. The 
Ciprofloxacin floating tablets were prepared by using polymers like HPMC K4M, HPMC 
K15M.From the result concluded that the floating lag time increases with increase hardness. 
HPMC K15M   shows better control release than other formulation and marketed product. 
Balachandra M. Habade et al.,44 In this present work attempt to prepare floating drug 
delivery with  prolong gastric residence time. The release of Ciprofloxacin from formulation 
is proportional to the concentration of polymer. As concentration of polymer increases the 
drug release decreases. This study floating tablets were prepared by using sodium bicarbonate 
as a gas generating agent in methocel polymer of different grades. 
Ravindra J. Salunke et al.,45 The purpose of current study is to develope and optimize a 
Hydro dynamically balanced system of ciprofloxacin Hcl as a single unit capsules using 
Response surface methodology.The formulation were prepared by using HPMC K4M, 
carbopol 934 and the amount of drug Release after 12hours was noted. The formulation were 
evaluated for in-vitro buoyancy and in-vitro release studies. 
E.Sathishreddy et al46 Sustained release floating tablets of Ciprofloxacin were successfully 
prepared with hydrophilic polymer like HPMC K15M.From the pre formulation studies of 
drug excipient compatibility was observed and it found that there is no such type of 
incompatibilities was existed. The formulation batches were evaluated for physical 
parameters, floating properties and dissolution profile. The drug content of all tablets was in 
the range of 98-102%. 
N.H Foda et al.,24The purpose of this work is to study the various antibiotic drugs 
thatformulated in gastro retentive drug delivery system. The present study was showed the 
development of gastro retentive drug delivery system for various antibiotic which used to 
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increase the bioavailability of drug and also increases the gastric residence time that leads to 
release of drug for long period of time in controlled manner. 
Rajinikanth PS  et al.,25 Developed gastro retentive floating tablets of amoxicillin for use in 
treatment of gastric infections that caused in stomach by microorganisms. The developed 
floating tablets are evaluated for physical parameters and in-vitro drug release characteristics. 
Sodium bicarbonate with combination of citric acid used as gas generating agent. This 
formulation is highly effected to cure H.pylori infection that occurred in stomach. 
Kunal P Nayak et al.,27Assessted the various approaches in gastro retentive drug delivery 
system and list out their advantages and disadvantages in delivering various types of drugs to 
stomach. They list out the various approaches like low density, high density, bioadhesive 
drug delivery systems ,magneticswellable and expandable drug delivery system that used to 
prolong the gastric retension time there by increase bioavailabiity of various drugs. 
Whithead L.  et al.,26Formulated and evaluated amoxicillin floating tablets using various 
hydrophilic polymers. Sodium alginate used as floating agent and the formulated tablets are 
evaluated for in-vitro drug release. The floating tablets of amoxicillin showed desired release 
of drug and also increases buoyancy help to increase gastric residence time thereby enhances 
the bioavailability of drug. 
Nayak A.K  et al.,29The purpose of this work is to study detail about gastro retentive drug 
delivery system and various approaches of gastro retentive system. These drug delivery 
increase the gastro retentive time and bioavailability of various drugs. It also known as site 
specific drug delivey system that delivers drug to stomach to treat various diseases like 
peptic, gastric ulcers and infections that caused by various microorganisms. 
Ali J.  et al.,47 Developed bioadhesive tablets of ofloxacin to deliver drug to stomach to treat 
gastric infections. The tablets are developed by using various mucoadhesive polymers like 
chitosan,sodium alginate, methocel polymers. These mucoadhesive tablets are used to 
enhance the bioavailability of ofloxacin by increasing the gastric residence 
time.Theseshowscontrolled release of drug for a prolong period of time. 
DebjitBhowmik et al.,48 A novel floating controlled-release drug delivery system was 
formulated in an effort increase the gastric retention time of the dosage form and to control 
drug release. One of the most feasible approaches for achieving a prolonged and predictable 
dug delivery profiles in the gastrointestinal tract is to control the gastric residence time, using 
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gastroretentive dosage forms that will provide us with new and important therapeutic options. 
Floating matrix tablets are designed to prolong the gastric residence time after 
oraladministration, at a particular site and controlling the release of drug especially useful for 
achieving controlled plasma level as well as improving bioavailability. 
 
Raju D. B  et al.,49 Sustained release gastroretentive dosage forms enable prolonged and 
continuous input of the drug to the upper parts of gastrointestinal tract and improve the 
bioavailability of medication that is characterized by narrow absorption window. 
Gastroretentive floating drug delivery systems (GFDDS) of Metformin hydrochloride, an 
antidiabetic drug with an oral bioavailability of only 50 %( because of its poor absorption 
from lower gastrointestinal tract) have been designed and evaluated. Hydroxy propyl methyl 
cellulose (HPMC K4M) and carbopol 934P were used as polymers and sodium bicarbonate 
as gas generating agent to reduce floating lag time. Tablets were prepared by wet granulation 
method. Floating tablets were evaluated for hardness, friability, weight variation, drug 
content, floating properties and in vitro release pattern. The in vitro drug release followed 
first order kinetics and drug release was found to be diffusion controlled. 
 
Kshirsagar R.V et al.,50The objective of the present study was to develop a hydro 
dynamically balanced system of Metformin as a single unit floating tablet. Various grades of 
low-density polymers were used for the formulation of this system. They were prepared by 
physical blending of Metformin and the polymers in varying ratios. The formulation was 
optimized on the basis of in vitro buoyancy and in vitro release in simulated gastric fluid pH 
1.2. Effect of Carbopol as a release modifier was studied to ensure the delivery of drug from 
the floating tables over a prolonged time period. Tablets prepared with HPMC K15M and 
Carbopol gave the best in vitro percentage release and were taken as the optimized 
formulation. By fitting the data into zero order, first order, Korsmeyer and peppas, and 
Higuchi model it was concluded that the release followed Korsmeyer and peppas release, as 
the correlation coefficient (R2 value) was higher for Korsmeyer and Peppas release. All the 
six formulations produced robust tablets with optimum hardness, consistent weight 
uniformity and low tablet friability. In vitro drug release tests of these tablets indicated 
controlled sustained release of Metformin HCl and 96-99% released at the end of 8hr in 
formulation containing high viscosity polymers. 
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PoonamSalunke et al.,51Ionotropic gelation technique can successfully used for preparation 
of Metformin hydrochloride microcarriers using different permeability polymer and gas 
forming agent. Various formulation variables such as concentration of gas forming agent 
combination of polymer, calcium chloride concentration, cross linking time were used, which 
are influenced to the drug entrapment efficiency, particle size and shape, floating behavior, 
and in-vitro drug release. The FTIR and DSC studies did not reveal any significant drug 
interactions. From above all results we conclude that CaCO3 is more suitable for sustained 
drug delivery system as compared to NaHCO3. The formulation M5 shows the satisfactory 
results of evaluation parameters, it remains floated up to 24 hrs. Shows 94% drug release 
within 24 hrs. It means this formulation is suitable for floating sustained drug delivery 
system. 
 
Brijesh S.Dave et al.,52developed a gastroretentive drug delivery system of Ranitidine 
hydrochloride .Guar gum, Xanthan gum, and Hydroxy propyl methyl cellulose used as a gel 
forming agents. Sodium bicarbonate was incorporated as a gas- forming agent. The effect of 
citric acid and stearic acid on drug release profile and floating properties were investigated. 
He concluded HPMC K4M and NaHCO3 were essential to achieve in vitro buoyancy. By 
selecting suitable composition of citric acid (release rate enhancer) and stearic acid (release 
rate retardant) the dissolution profile can be achieved.  
 
Ichikawa et al.,53 developed a new multiple type of floating dosage system composed of 
effervescent layers and swellable membrane layers coated on sustained release pills. The 
inner layer of effervescent agents containing sodium bicarbonate and tartaric acid was 
divided into 2 sublayers to avoid direct contact between the 2 agents. These sublayers were 
surrounded by a swellable polymer membrane containing polyvinyl acetate and purified 
shellac. When this system was immersed in the buffer at 37°C, it settled down and the 
solution permeated into the effervescent layer through the outer swellable membrane. CO2 
was generated by the neutralization reaction between the 2 effervescent agents, producing 
swollen pills (like balloons) with a density less than 1.0 g/mL. It was found that the system 
had good floating ability independent of pH and viscosity and the drug (para-amino benzoic 
acid) released in a sustained manner. 
 
Li  et al.,54 evaluated the contribution of formulation variables on the floating properties of a 
gastro floating drug delivery system using a continuous floating monitoring device and 
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statistical experimental design. The formulation was conceived using taguchi design. HPMC 
was used as a low-density polymer and citric acid was incorporated for gas generation. 
Analysis of variance (ANOVA) test on the results from these experimental designs 
demonstrated that the hydrophobic agent magnesium stearate could significantly improve the 
floating capacity of the delivery system. High-viscosity polymers had good effect on floating 
properties. The residual floating force values of the different grades of HPMC were in the 
order K4 M > E4 M > K100 LV > E5 LV but different polymers with same viscosity, i.e., 
HPMC K4M, HPMC E4M did not show any significant effect on floating property. Better 
floating was achieved at a higher HPMC/carbopol ratio and this result demonstrated that 
carbopol has a negative effect on the floating behavior. 
Nur and Zhang  et al.,55 developed floating tablets of captopril using HPMC (4000 and 15 
000 cps) and carbopol 934P. Invitro buoyancy studies revealed that tablets of 2 kg/cm2 
hardness after immersion into the floating media floated immediately andtablets with 
hardness 4 kg/cm2 sank for 3 to 4 minutes and then came to the surface. Tablets in both cases 
remained floating for 24 hours. The tablet with 8kg/cm2 hardness showed no floating 
capability. It was concluded that the buoyancy of the tablet is governed by both the swelling 
of the hydrocolloid particles on the tablet surface when it contacts the gastric fluids and the 
presence of internal voids in the center of the tablet (porosity). A prolonged release from 
these floating tablets was observed as compared with the conventional tablets and a 24-hour 
controlled release from the dosage form of captopril was achieved. 
 
Talwar et al.,56 developed a once-daily formulation for oral administration of ciprofloxacin. 
The formulation was composed of 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% 
xanthum gum, 13.7% sodium bicarbonate, and 12.1% cross-linked poly vinyl pyrrolidine. 
The viscolysing agent initially and the gel-forming polymer later formed a hydrated gel 
matrix that entrapped the gas, causing the tablet to float and be retained in the stomach or 
upper part of the small intestine (spatial control). The hydrated gel matrix created a tortuous 
diffusion path for the drug, resulting in sustained release of the drug (temporal delivery). 
 
Praveen Nasa  et al.,57From the present study, it was concluded that the formulation F5 
(containing 160 mg of Methocel K100M and 40 mg of Methocel E50) was the optimum 
formulation amongst all the test batches. It exhibited satisfactory pre-compression properties, 
as well as, showed satisfactory dissolution profile as a sustained release formulation. Not 
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only this, the formulation was also found to possess appropriate floating characteristics, as 
revealed in the in vitro buoyancy studies. Moreover, the dissolution profile of the optimized 
formulation showed similarity to the marketed formulation. Therefore, it may be concluded 
from the investigation that a combination of Methocel K100M and Methocel E50 in the ratio 
of 4:1 may be satisfactorily used in the formulation of floating drug delivery system for a 
freely soluble drug such as Metformin. 
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3. AIM AND OBJECTIVE 
Ciprofloxacin Hcl is commonly known as broad spectrum antibiotic medicine which 
is used to treat infections caused by gram positive and gram negative microorganism. These 
also prescribed in treatment of respiratory and urinary tract infections. Ciprofloxacin 
conventional tablets have been used from long period of time for the treatment of bacterial 
infections.CiprofloxacinHcl is an acidic drug which is primarily absorbed in stomach. The 
bioavailability of Ciprofloxacin is 69% and its half life is 4 hours. 
The present investigation of work is to prepare Ciprofloxacin floating tablets by using 
polymers like HPMC K4M, Eudragit 100S, guar gum, and the prepared tablets are 
characterized by using different evaluation parameters like buoyancy lag time, floating time, 
in-vitro drug release, uniformity of drug content, hardness, friability etc.And the best suited 
formulation of Ciprofloxacin Hcl is compared with marketed product. 
 To improve half life  which shows prolong action of drug in controlled manner for 
long period in stomach.  
 To increase bioavailability of drug by increasing gastric residue time. 
 Ciprofloxacin floating tablets are used to decrease dose frequency of drug also avoid  
fluctuations that cost by conventional tablets and also it helps to reduce the adverse 
effects caused by ciprofloxacin at higher doses. 
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4. PLAN OF WORK 
 
It was planned to carry out the following 
 
PART-1 
 
1. Estimation of Ciprofloxacin Hcl drug 
2. Drug-Polymer compatibility studies by FTIR 
3. Preparation of granules for Ciprofloxacin Hcl floating tablets 
4. Preformulation studies of granules by 
 Angle of repose 
 Bulk density 
 Tapped density 
 Compressibility index 
 Hausner’s ratio 
 
PART-2 
 
1. Compression of granules in tablets 
2. Characterization of Ciprofloxacin Hcl floating tablets by 
 Hardness test 
 Friability test 
 Weight variation 
 Diameter 
 Thickness 
 Drug content uniformity 
 Buoyancy lag time 
 Floating time  
3.  In-vitro dissolution studies 
4. Stability studies 
5.  Kinetic analysis of dissolution data 
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5. DRUG PROFILE 
 
CIPROFLOXACIN58,59 
 
 
Description of Ciprofloxacin 
                        Ciprofloxacin is faintly yellowish to light yellow crystalline powder 
 
Chemical Data 
           Chemical name : 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)- 
                                                            Quinoline-3-carboxylic acid 
           Formula  : C17 H18 F N3 03 
 Molecular mass : 331.346 g/mol 
 
Physical Data 
 Solubility  :  Freely soluble in distilled water, Phosphate buffer PH        
                                                           6.8 & 7.5 
 Melting point  : 255-257ºC 
 Drug Category : Fluoroquinolones 
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Pharmacokinetic   Data 
           Absorption   : Rapidly and well absorbed from GIT with peak  
plasmaConcentration   after 2hours                                             
           Bioavailability  : 69% 
 Half life   : 4 hours 
 Distribution   : Bile (high concentration) , CSF(10%)  ,crosses  
placentalbarrier 
           Protein binding  : 20-40% 
  Metabolism   : Hepatic including CYP A2 
           Excretion   : Renal (major), non renal routes like hepatic,  
biliyarytransluminal Secretion 
Analytical Data 
 Absorption maxima  : 277nm 
 pKa value   : 6.09 
 
Mechanism of Action 
 Ciprofloxacin Hcl   drug has invitro activity against a wide range of gram negative 
and gram positive organism. Ciprofloxacin inhibits bacterial DNA gyrase, an enzyme 
Responsible for countering excessive supercoiling of DNA during replication of transcription 
.But the mechanism action of Ciprofloxacin is different from other antimicrobial agents such 
as Beta lactum,tetracyclins, aminoglycosides therefore organism resistant to these drug may 
susceptible to Ciprofloxacin Hcl drug. 
Uses60 
             Ciprofloxacin is used for treatment of a number of infections including infection of 
Joints and bones, gastroenteritis, malignant otitis externa, respiratory tract infections,  
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cellulities, urinary tract infections, anthrax, skin structural infections, typhoid fever. 
Ciprofloxacin Hcl also used in treatment of community acquired pneumonia, chronic 
bacterial prostastitis, nosocomial pneumonia etc.. 
Brand Names   : Cipro, Cipro XR, Proquin XR, Ciloxan. 
Available Dosages  : Tablets, Intravenous solutions, eye and ear drops 
Dosing   : Adult dose is 250-750mg (immediate release tablets) for                               
Every 12hours or 500-1000mg (extended release 
tablets), 200-400mg (i.v),Child dose is 200-400mg/kg 
bid 
Contraindications 
 Ciprofloxacin administration may become contra indicated to some drugs thatmay 
metabolize by enzyme CYP A2 and some drugs like Tizanidine. Ciprofloxacin 
Contraindicated in persons with a history of hypersensitivity to this drug and other quinoline 
drugs. 
Pregnancy 
            Ciprofloxacin comes under pregnancy category C where there is no evidence studies 
of Ciprofloxacin in pregnant women so it should not used during pregnancy. 
Nursing Mothers 
            Ciprofloxacin should avoid in nursing women. 
Pedriatic population 
            Ciprofloxacin should not used in infants as they have not developed sufficient 
enzymes to metabolise drug and it should not used to children via intravenous route. 
Adverse reactions 
 Ciprofloxacin may cause mild adverse reactions like nausea, vomiting, diarrhoea, 
rashes, abnormal liver functions and it may cause some rare but serious adverse effects like 
Myasthenia gravis including muscle weakness, breathing problem, neuropathy, 
photosensitivity reactions etc. 
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Drug Interaction 
            Ciprofloxacin may interact with some drugs like amoxicillin, trimethoprim, 
azithromycin, cephalexin and some herbal and natural supplements. This drug can interact 
with NSAIDS causes Black box warning which leads to Achiles tendon rupture. 
Storage 
 Oral products should be stored at 5±25ºC, Ophthalmic products should be stored At 
2±25ºC intravenous solutions should be stored at 25ºC 
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6. POLYMER AND EXCIPIENTS PROFILE 
EUDRAGIT61,62,63 
 
 Nonproprietary Names  : Ph.Eur:Ammonio methacrylate copolymer 
      USP/NF: Ammonio methacrylate copolymer NF 
 
Synonyms    : Acrylates, ammonium methacrylate copolymer  
 
 
Chemical Name                                : Poly(ethyl acrylate copolymer co-trimethyl 
     Ammonioethyl methacrylate chloride) 
 
Description 
 Eudragit 100S polymer is a white crystalline powder with faint amine like odour. 
 
Pharmaceutical Applications  
 Eudrgit is an advance polymer which is widely used nowadays. Eudragit is used 
infilm coating and enteric coating for tablets. It also used in sustain release formulations. 
Eudragitused in ophthalmic drug delivery system to prepare ocular drug delivery system. 
Eudragit also used in vaginal drug delivery to prepare intra vaginal tablet and it used in 
preparation of  buccal sublingual formulations. Eudragit polymer also widely used in gastro 
retentive drug delivery system in preparation of pH dependent and floating tablets. It is also 
used in gene delivery and vaccine delivery in the form of microspheres and nano particles etc. 
 
Stability and Storage Conditions 
 Eudragit powder is a stable material at room temperature. It should stored in well 
closed container and should be protected direct contact with sunlight and stored at room 
temperature. 
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GUAR GUM 
 
 
 
Nonproprietary  Names  : BP: Guar galactomannan, phEur: guar      
USPNF: gar gum galactomannan. 
Synonyms    : Galactosal: guar flour: jaguar gum; meyprofin 
Chemical   name   : Galactomannan polysaccharide 
Empirical formula   : C6 H12 O6 
Molecular weight   : 220.00 g/mol 
Description    : Guar gum is aodourless, white to yellowish  
powder with bland taste.   
Applications in pharmaceutical technology,61-63 
 Guar gum commonly used in cosmetics, food products and pharmaceutical 
formulations. It also used in preparation of sustain release matrix tablets in place of cellulose 
derivatives. It also used solid dosage form as binder and disintegrant. Guar  gum also used in 
some oral and topical products as a suspending agent, thickening agent and stabilizing agent. 
Guar gum used in gastro retentive drug delivery like floating drug delivery system etc. These 
polymer also used in preparation of creams and ointments as stabilizing agent. Guar gum is a 
natural polymer which also used as binding agents in formulation of oral dosage form 
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Stability and storage condition 
 Guar gum is stable at PH 4.0-10.5 and the powder should be stored in a  well closed 
container in a cool, dry place and should be avoid direct contact with sunlight. 
 
HYDROXY PROPYL METHYL CELLULOSE 
 
 
 
 
Nonproprietary name : BP:Hypermellose , IP:Hydroxy propyl methyl 
 
     cellulose, phEur: Hypermellosum, USP:Hypermellose 
Synonyms   : HPMC, Methocel, methyl cellulose propylene  
     glycolether,  Metalose, tylopur 
Chemicalnames  : Cellulose hydroxyl propyl methyl ether 
Empirical formula  : (O CH2 CH (OH) CH3) 
Molecular weight  : 10000-500000 g/mol 
Description   : HPMC is an odourless and tasteless white or  
     creamywhite fibrous or granular powder 
Applications in pharmaceutical technology,61-63 
 HPMC widely used in oral, ophthalmic and topical pharmaceutical forrmulations. In 
oral products it is mainly used as tablet binder, film coating agent and also matrix used in 
extended release tablet formulation. HPMC also used as suspending and thickening agent in 
topical formulations. It also used as stabilizing and emulsifying agent in topical gels and 
ointments. In additional it used in manufacturing of capsules, as an adhesion in plastic 
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bandages and as a wetting agent for hard contact lenses. HPMC also used in cosmetic and 
food products.HPMC polymer also used in preparation of gastro retentive dosage form. 
Stability and storage condition 
 HPMC  K4M  is a stable material but it is hygroscopic after drying. It stable.at pH 3-
11 and it should be stored in well closed container in a cool and dry place. 
 
SODIUM BICARBONATE 
 
 
 
Nonproprietary name64 : Backing soda, bread soda, cooking soda, bicarbonate of 
     soda 
Synonyms   : Sodium bicarb, bicarb sodium, bicarb 
Chemical name  : Sodium hydrogen carbonate 
Molecular formula  : NAHCO3 
Molecular mass  : 84.007g/mol 
Description   : It is aodourless white crystal or powder which is soluble 
     in Water 
Applications in pharmaceutical technology 
 Sodium bicarbonate used as preservative and antiseptic agents. It also used as 
effervescent agent in floating tablets. It also used in personal hygiene as product preparation 
of toothpaste. It also used as a cleansing agent and scrubbing agent. It mainly used in 
treatment of acidosis as a antacids and it can used to treat digestive disorders and urinary 
alkalinisation. 
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Stability and storage conditions 
 Sodium bicarbonate is a stable in dry air at room temperature. In moist air it 
decompose by generating carbon dioxide. It should be stored in tight well closed container in 
a cool and dry place should be avoid direct sunlight.  
CITRIC ACID 
 
 
Nonproprietary name64 : 3-carboxy-3-hydroxypentanedioic acid,2- hydroxy - 
     1,2,3- Pro Panetri carboxylic acid  
Chemical name  : 2-hydroxy propane -1, 2, 3- tri carboxylic acid 
Molecular formula  : C6 H8 O7 
Molecular mass  : 92.1235 g/mol 
Description   : Citric acid is aodourless, crystalline white solid  
     granular to Fine powder with strong acidic taste 
 
Applications in pharmaceutical technology 
 Citric acid can used as flavouring agent and preservative in food and especially in soft 
drinks and in ice creams. It also used as emulsifying agent in ice creams and also used as 
cleaning and chelating agent in hard water. In combination with  sodium bicarbonate it used 
as gas generating agent. It also used in cosmetic preparation and pharmaceutical agent. Citric 
acid also used as a ingredient of antiviral tissue. It can also usedas colouring agent and adult 
ant in food industries. 
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Stability and storage conditions  
 Citric acid monohydrate may stored for 36months from date of manufacturing. It 
should be stored at relative humidity of 50% and a temperature range of 10±30ºC. It should 
be stored in well closed container and avoid direct contact with sunlight. 
 
MAGNESIUM STEARATE 
 
 
Nonproprietary name64 : Magnesium salt 
Synonym   : Octadecanoic acid, magnesium salt 
Chemical name  : Magnesium octadecanoate 
Molecular formula  : Mg (C18 H35 O2)2 
Molecular mass  : 591.27g/mol 
Description   : Magnesium stearate is a very fine, light white powder  
     milled powder with characteristic taste  with slight  
     odour which is greasy to touch. 
Applications in pharmaceutical technology 
 Magnesium stearate mainly used as a diluents in manufacturing of medical tablets, 
capsules and powder. It also used as lubricating agent that prevent sticking of the tablet to 
equipments. It can also used as food additives and also manufacturing of animal and 
vegetable oils. 
Stability and storage conditions 
  Magnesium stearate is a stable product which should be stored tightly in well closed 
container in cool and dry place and should be stored at room temperature. 
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STARCH 
 
 Nonproprietary Name64  : BP: Maize starch, Potato starch, Rice Starch 
Tapioca Starch, Wheat starchJP: Corn Starch, 
Potato Starch, Rice Starch, PhEur: Maize Starch, 
Pea Starch USP-NF: Corn Starch, Tapioca 
Starch, Potato  
 
Synonyms    : Amido; amidon; amilo; amylum; Pharmgel;  
      amylum; triticiamylum; fecule; maydisamylum 
 
Chemical Name   : Starch 
 
Empirical Formula   : (C6H 10O5) n 
 
Molecular Weight   : 300–1000 g/mol 
 
Description 
 Starch occurs as an odorless and tasteless, fine, white to off-white powder. It consists 
of very small spherical or ovoid granules or grains whose size and shape are characteristic for 
each botanical variety. 
 
Functional Category: 
 
 Tablet and capsule diluent; tablet and capsule disintegrant; tablet binder; thickening 
agent. 
 
Applications in Pharmaceutical Formulation or Technology: 
 Starch is a versatile excipient used primarily in oral solid-dosage formulations where 
it is utilized as a binder, diluent, and disintegrant. In tablet formulations, freshly prepared 
starch paste is used at a concentration of 3–20% w/w (usually 5–10%, depending on the 
starch type) as a binder for wet granulation. The required binder ratio should be determined 
by optimization studies, using parameters such as tablet friability and hardness, disintegration 
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time, and drug dissolution rate. Starch is one of the most commonly used tablet disintegrants 
at concentrations of 3–25% w/w; a typical concentration is 15%. Starch paste is used in 
ointment formulations, usually in the presence of higher ratios of glycerin. Starch has been 
investigated as an excipient in novel drug delivery systems for nasal and other site-specific 
delivery systems. Starches are useful carriers for amorphous drug preparations, such as 
pellets with immediate or delayed drug release obtained, for example, by melt extrusion and 
they can improve the bioavailability of poorly soluble drugs. Starch, particularly rice starch, 
has also been used in the treatment of children’s diarrheal diseases 
 
Stability and Storage Conditions 
 Dry starch is stable if protected from high humidity. Starch is considered to be 
chemically and microbiologically inert undernormal storage conditions. Starch solutions or 
pastes are physically unstable and are readily metabolized by microorganisms; they should 
therefore be freshly prepared when used for wet granulation. Starch should be stored in an 
airtight container in a cool, dry place. 
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7 . MATERIALS AND METHODS 
THE FOLLOWING MATERIALS USED IN THE PRESENT STUDY 
TABLE NO-1 
 
S.No MATERIALS USED SUPPLIER / MANUFACTURERS  
1 CIPROFLOXACIN HCL MNS laboratory, Hyderabad 
2 HPMC K4M Reddy’s lab, Hyderabad 
3 EUDRAGIT 100S Reddy’s lab, Hyderabad 
4 GUAR GUM Yucca enterprises, Mumbai 
5 SODIUM BICARBONATE Rankem lab, Gujarat 
6 CITRIC ACID Rankem lab, Gujarat 
7 MAGNESIUM STEARATE Himedia laboratories, Mumbai 
8 STARCH Finar chemicals, Ahmadabad 
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THE FOLLOWING EQUIPMENTS ARE USED IN PRESENT STUDY 
TABLE NO-2 
 
S.No EQUIPMENTS USED COMPANY/ SUPPLIER 
1 U.V.SPECTROPHOTOMETER Analytical spetro 2060 plus 
2 ELECTRONIC BALANCE Eagle instrument pvt. 
3 FOURIER TRANSFORM  INFRA 
REDSPECTROSCOPY  (FTIR) 
Perkin Elmer ND Spectrum RX1 
4 TABLET PUNCHING MACHINE Cadmach  punching machine 
5 HARDNESS TESTER SSN tablet hardness tester 
6 FRIABILATOR Electro laboratories 
7 
DISSOLUTION APPARATUS 
Electronic India microprocessor dissolution 
apparatus 
8 BESTO VERNIER CALIPERS Electro laboratories 
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EXPERIMENTAL STUDIES 
 
CALIBRATION CURVE OF CIPROFLOXACIN HYDROCHLORIDE 
ANALYTICAL METHODS:  
CALIBRATION OF CIPROFLOXACIN HYDROCHLORIDE:  
 A spectrophotometric method based on the measurement of absorbance 277 nm in a 
0.1 HCl was used in the present study for the estimation of Ciprofloxacin HCl.  
 
REAGENTS:  
Preparation of 0.1N HCl65,66:  
8.5ml of Concentrated HCl was taken in a volumetric flask and it was made up to 
1000ml with distilled water.  
 
STANDARD SOLUTION:  
100mg of Ciprofloxacin HCl pure drug was dissolved in 100ml of 0.1N Hcl(stock 
solution) 10ml of solution was taken and make up with100ml of 0.1N Hcl(100μg/ml). 
.  
PROCEDURE:  
 From the standard solution aliquots of 2ml, 4ml, 6ml, 8ml,10ml were pipette out to 
100 ml standard measuring flask and made up to 100 ml with 0.1 N HCl. The absorbance of 
the above solutions was measured in UV-spectrophotometer at 277 nm using0.1N HCl as 
blank. Then a graph was plotted by taking Concentration on X-Axis and Absorbance on  Y-
Axis which gives a straight line which indicates the drug is pure.    
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Table -3:  calibration curve of Ciprofloxacin 
 
S.No Concentrations(µg/ml) Absorbance (nm) 
1 0 0.000 
2 2 0.107 
3 4 0.219 
4 6 0.342 
5 8 0.441 
6 10 0.542 
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Fig 5: Standard curve of Ciprofloxacin Hcl 
 
COMPATABILITY STUDIES BY FTIR STUDIES 
 
Drug-polymer compatibility studies:65 
FTIR analysis: 
 Infrared spectroscopy was conducted using an Perkin Elmer FTIR combined to PC 
(with spectrum 2000 analysis software) was recorded in region of 4000 to 400 cm. The 
procedure consisted of dispersing a sample as shown in table in KBr and compressing into 
discs by applying a pressure of 5 tons for 5min in a hydraulic press. The pellet was placed in 
light path and the spectrum was obtained. 
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Table 4: Composition of drug and polymers samples for IR studies 
 
     S. No                    SAMPLES FOR FTIR STUDIES 
       1 Ciprofloxacin Hcl 
       2 HPMC K4M 
       3 Eudragit 100S 
       4 Guar gum 
       5 Ciprofloxacin Hcl + HPMC K4M 
       6 Ciprofloxacin Hcl + Eudragit 100S 
       7 Ciprofloxacin Hcl+ Guar gum 
       8 Ciprofloxacin Hcl+ HPMC K4M+ Eudragit 100S+ Guar gum+ Sodium 
bicarbonate+ Citric acid 
 
3. PREPARATION OF CIPROFLOXACIN HYDROCHLORIDE FLOATING    
TABLETS 66 
                    Floating tablets of Ciprofloxacin Hcl were prepared by wet granulation technique 
using various polymers like HPMC K4M, Eudragit100S, Guar gum with combination of 
sodium bicarbonate and citric acid as gas generating agent. The composition of each 
formulation is given in formulation table no - 5. Totally seven batches of granules were 
prescribed by using different single and combination of polymers.F1 contains 150mg of 
HPMC K4M, F2 contains150mg of Eudragit 100S, F3 contains 150mg of guar gum, F4 
contains 75mg of HPMC K4M and 75mg Eudragit 100S, F5 contain 75mg of Eudragit 
100Sand 75mg of guar gum, F6 contain 75mg of HPMC K4M and 75mg guar gum, F7 
contains 50mg of HPMC K4M, 50mg Eudragit 100S and 50mg guar gum. Magnesium 
stearate used as a lubricant. 
 Ciprofloxacin Hcl is passed through sieve no.20, HPMC K4M,Eudragit 100S,Guar 
gum, sodium bicarbonate, citric acid passed through sieve no.40. Magnesiunstearate is passed 
through sieve no 60. The shifted materials of Ciprofloxacin Hcl was geometrically mixed 
with polymer and sodium bicarbonate and citric acid and blended for 10minutes.Then add 
starch mucilage slowly drop wise manner to form a coherent mass.The formed coherent mass 
was sieved manually through sieve no.16 to form granules. Then the granules are collected 
and dried in hot air oven at 400C ± 20C for 2 hours. The dried granules were passed through 
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sieve no.20. Magnesium stearate is added to the dried granules then subjected to pre 
formulation studies. After the completion of preformulation studies, the granules of all 
formulations were compressed into tablets by using  tablets punching machine 
Table-5: Formulation of Ciprofloxacin Hcl floating tablets 
Formulati
on 
Batches 
Ciproflox
acin    Hcl  
(mg) 
HPMC 
K4M 
(mg) 
Eudragit 
100S 
(mg) 
Guar 
gum 
(mg) 
Sodium 
bicarbon
ate 
(mg) 
Citric 
acid 
(mg) 
Starch 
mucila
ge 
(mg) 
Magnesium 
stearate 
(mg) 
F1 250 150 - - 50 15 25 10 
F2 250 - 150 - 50 15 25 10 
F3 250 - - 150 50 15 25 10 
F4 250 75 75 - 50 15 25 10 
F5 250 - 75 75 50 15 25 10 
F6 250 75 - 75 50 15 25 10 
F7 250 50 50 50 50 15 25 10 
Weight of each tablet – 500 mg 
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PREFORMULATION STUDIES 
Bulk Density:67 
  It refers to a measurement to describe packing of particles. Bulk density is used to 
determine the amount of drug that occupies the volume in mg/ml 
Procedure: 
It is the ratio of total mass of powder to the bulk volume of powder. It was measured 
by pouring the weighed powder in to a measuring cylinder and the initial volume was noted. 
This initial volume is called bulk volume. The powder was tapped 3 times till a constant 
volume called bulk density was obtained. From this, the bulk density is calculated according 
to the formula mentioned below. It is expressed in g/ml and is given by 
 
 
 
 
  Where, 
        m    =  mass of the granules 
     vb =  bulk volume 
Tapped Density:67 
After determining the poured bulk density,Weighed quantity of API was taken into a 
graduated cylinder. Volume occupied by DRUG was noted down. Then the cylinder was 
subjected to 500, 750 & 1250 taps in tap density tester (Electro Lab USP II). According to 
USP, the blend was subjected for 500 taps. % Volume variation was calculated and subjected 
for additional 750 taps. % Variation is calculated.   
 
 
 
              Tapped bulk density=Mass of powder/Tapped volume of the powder. 
 
 
Pb=m/vb 
Pt= m/vt 
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Compressibility Index: 
 
Weighed API was transferred to 100ml-graduated cylinder and subjected to 
500,750&1250 taps in tap density tester (Electro lab). The difference between two taps 
should be less than 2%. The %of compressibility index calculated using formula 
 
 
Limits : 
S.No Compressibility index Flow 
1 5-12 Free flow 
2 12-16 Good flow 
3 18-21 Fair 
4 23-25 Poor 
5 33-38 Very Poor 
6 >40 Extremelypoor 
 
  
Hausner’s Ratio:  
It is measurement of frictional resistance of the drug. The ideal range should be                
1.2 –1.5. It is the determined by the ratio of tapped density and bulk density. 
Hausner’s ratio = vi/ vb 
Where       
 vt   = Tapped volume     
 vi   =  Bulk volume 
 
CI = vb –vt/ vb X 100 
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      Limits: 
  
S. No Hausner’ ratio Flow 
1 1.0-1.11 Excellent 
2 1.1-1.18 Good 
3 1.19-1.25 Fair 
4 1.26-1.34 Possible 
5 1.35-1.45 Very poor 
6 ˃1.60  Very very poor 
 
Angle of repose:69 
 Angle that can be obtained between the free surface of a powder heap and horizontal 
plane. The angle of repose was measured by allowing the powders to fall over a graph sheet 
placed on horizontal surface through a funnel kept at a certain convenient height (about 2 
cm).  
 The height of the heap was measured and then circumference of the base of heap was 
drawn on a graph sheet with the help of a pencil. The radius of the circle obtained was 
measured. The angle of repose is given as,  
θ=tan-1 (h/r)  
Where   
  Θ =  angle of repose  
   H =  height of the heap  
   R = radius of the base of the heap  
Limits: 
Angle of Repose (Degrees) 
 
Type of Flow 
 
<20 
 
Excellent 
 
20-30 Good 
 
30-34 
 
Passable 
 
>40 
 
Very Poor 
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CHARACTERIZATION OF CIPROFLOXACIN HCL FLOATING 
TABLETS 
The formulated tablets were evaluated for the following physicochemical 
characteristics:  
 Various standards have been set in the various pharmacopoeias regarding the quality 
of pharmaceutical tablets. These include thickness, size, diameter, shape, weight, hardness, 
disintegration and dissolution characters. The diameter and shape depends on the die and 
punches selected for the compression of tablets. The remaining specifications assure that 
tablets do not vary from one production lot to another. The following standards or quality 
control tests were carried out on Ciprofloxacin floating tablets . 
General appearance:70-71 
The general appearance of tablets, its visual identity and overall  “Elegance” is 
essential for consumer acceptance, control of lot-to-lot uniformity and general tablet-to-tablet 
uniformity and for monitoring the production process. The control of general appearance 
involves measurement of attributes such as a tablets size, shape, colour, presence or absence 
of odour, taste, surface textures, physical flows and consistency. 
The formulated tablets were assessed for its general appearance and observations 
were made for shape, color, texture and odour.   
 
 Hardness test:65 
Hardness of the tablet was determined by using the Monsanto hardness tester. The 
lower plunger was placed in contact with the tablet and a zero reading was taken. The plunger 
was then forced against a spring by turning a threaded bolt until the tablet fractured. As the 
spring was compressed a pointer rides along a gauge in the barrel to indicate the force.  
 
Weight Variation:72 
20 tablets were selected and weighed collectively and individually. From the 
collective weight, average weight was calculated. Each tablet weight was then compared with 
average weight to ascertain whether it was within permissible limits or not. Not more than 
two of the individual weights deviated from the average weight by more than 5% for 500 mg 
tablets and none by more than double that percentage.  
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  The percentage deviation was calculated by using following formula 
% Deviation = (Individual weight – Average weight) / Average weight x 100 
Limits: 
 
Average weight of a tablet %deviation 
130 mg or less ±10 
ҹ130 mg and Ҹ 324 mg ±7.5 
324 mg or more ±5.0 
 
Friability test:69 
Friability is the loss of weight of tablet in the container/package due to removal of 
fine particles from the surface. This test is applicable to compressed tablets and is intended to 
determine the physical strength of tablets. 
 It is usually measured by the use of Roche friabilator. The drum is attached to the 
horizontal axis of a device that rotates at 25 ± 1 rpm. It should be ensured that with every turn 
of the drum the tablets roll or slide and fall on to the drum wall or onto each other. 
 Ten tablets are weighed (w1) and placed in the apparatus where they are exposed to 
rolling and repeated shocks as they fall 6 inches in each turn within the apparatus. After 4 
minutes of this treatment or 100 revolutions, the tablets are weighed (w2) and this weight was 
compared with the initial weight of tablet. The loss of weight may be due to abrasion is a 
measure of the tablet friability. The value is expressed in percentage. A maximum loss of 
weight not greater than 1% is acceptable for most tablets. 
if the tablets are cracked, chipped or broken after tumbling, the sample fails the test. The 
friability was determined using the following formula: 
 1 2
1
w - w
friability =  x 100
w
 
Where, 
w1 = weight of ten tablets before test 
w2 = weight of ten tablets after test. 
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Estimation of Drug Content:66 
20 tablets of each formulation were weighed and powdered. The quantity of powder 
equivalent to 100 mg of Ciprofloxacin Hydrochloride was transferred in to a 100 ml 
volumetric flask and volume made up with0.1N HCl. Further 1ml of the above solution was 
diluted to 10 ml with 0.1N HCl and absorbance of the resulting solution was observed at 277 
nm. 
Floating test:70 
 The tablets were placed in a 100ml beaker containing 0.1N Hcl. The time between 
introducing of dosage form and its buoyancy on 0.1N Hcl and the time during at whichthe 
dosage form remain buoyant were measured. 
Buoyancy lag time:37 
 The time taken for the dosage form to emerge on surface of medium is Called 
Floating lag  time (FLT). Total duration of time during which the dosage form remains 
buoyant is called Total floating time (TFT). 
IN VITRO DISSOLUTION STUDIES OF TABLETS:66 
Dissolution parameters:  
Apparatus   -- USP-II, Paddle Method 
Dissolution Medium   -- 0.1 N HCl 
RPM     -- 50 
Sampling intervals (hrs) -- 1,2, 3,4,5, 6,7, 8,9,10,11 and 12hour 
Temperature   -- 37°c + 0.5°c 
 Dissolution Study: 
As the preparation was for floating drug release given through oral route of 
administration, different receptors fluids are used for evaluation the dissolution profile.] 
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Procedure:  
900ml 0f 0.1 HCl was placed in vessel and the USP apparatus –11 (Paddle Method) 
was assembled. The medium was allowed to equilibrate to temp of 37°c + 0.5°c. Tablet  was 
placed in the vessel and the vessel was covered the apparatus was operated for 12 hours and 
then the medium 0.1 N HCl was taken and process was continued from 0 to 12 hrs at 50 rpm. 
At definite time intervals of 5 ml of the receptors fluid was withdrawn, filtered and again 5ml 
receptor fluid was replaced.  Suitable dilutions were done with receptor fluid and analyzed by 
spectrophotometrically at 277 nm using UV-spectrophotometer.  
Stability studies 
 The concentration of an active ingredient of any formulation may decrease with 
increase in temperature and time. This will lead to decrease the potency of the product. 
Stability study in different temperatures should be carried out to predict the stability of the 
formulations  
 Stability studies were aimed at determining the result of aging and storage under 
various conditions on the formulated floating tablets. Stability studies are used to find out 
whether any chemical degradation of ciprofloxacin formulations take place or not. The 
formulated tablets were stored at 4o 2oC (in refrigerator), 27o 2oC (in room temperature) 
and 45oC  2oC (in accelerated stability chamber) for 45 days. Three tablets were taken from 
all the stored samples at the intervals of 15th, 30th and 45th days and analysed for drug content 
and in vitro release studies were carried out to determine the percentage of ciprofloxacin 
released71 
KINETIC ANALYSIS OF DISSOLUTION DATA:72-76 
 The analysis of drug release mechanism from a pharmaceutical dosage form is an 
important but complicated process and is practically evident in the case of matrix systems. As 
a model-dependent approach, the dissolution data was fitted to five popular release models 
such as zero-order, first-order, diffusion and exponential equations, which have been 
described in the literature. The order of drug release from matrix systems was described by 
using zero order kinetics or first orders kinetics. The mechanism of drug release from matrix 
systems was studied by using Higuchi equation, erosion equation and Peppa’s-
Korsemeyerequation. The results are given in Table no 26 and the graphical representation 
are presented in fig no 24. 
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Zero Order Release Kinetics 
It defines a linear relationship between the fraction of drug released versus time. 
Q = kot 
Where, Q is the fraction of drug released at time t and kois the zero order release rate 
constant. 
A plot of the fraction of drug released against time will be linear if the release obeys zero 
order release kinetics. 
First Order Release Kinetics: 
 Wagner assuming that the exposed surface area of a tablet decreased exponentially 
with time during dissolution process suggested that drug release from most of the slow 
release tablets could be described adequately by apparent first-order kinetics. The equation 
that describes first order kinetics is 
                                                             In (1-Q) = - K1t 
Where, Q is the fraction of drug released at time t and k1 is the first order release rate 
constant. 
 Thus, a plot of the logarithm of the fraction of drug remained against time will be 
linear if the release obeys first order release kinetics. 
Higuchi equation: 
 It defines a linear dependence of the active fraction released per unit of surface (Q) on 
the square root of time. 
                                                         Q=K2t½    
Where, K2 is the release rate constant. 
A plot of the fraction of drug released against square root of time will be linear if the release 
obeys Higuchi equation. This equation describes drug release as a diffusionprocess based on 
the Fick’s law, square root time dependant. 
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Power Law: 
 In order to define a model, which would represent a better fit for the formulation, 
dissolution data was further analyzed by Peppa’s and Korsemeyer equation (Power Law). 
                                                                 Mt/M = K.tn 
Where,   Mt is the amount of drug released at time t and M is the amount released at 
time , thus the Mt/Mis the fraction of drug released at time t,k is the kinetic constant and n 
is the diffusional exponent. To characterize the mechanism for both solvent penetration and 
drug release n can be used as abstracted in Table. A plot between log of Mt/M against log of 
time will be linear if the release obeys Peppa’s and Korsemeyer equation and the slope of this 
plot represents “n” value. 
 
Diffusion exponent and solute release mechanism for cylindrical shape  
Diffusion Exponent Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n<0.89 Anomalous (non-fickian) diffusion 
0.89 Case II transport 
n>0.89 Super Case II transport 
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8. RESULTS AND DISCUSSION 
 The present study was undertaken to formulate ciprofloxacin floating tablets using 
three polymers and with three different ratios and prepared by wet granulation method. 
Before compression of the powder, evaluation studies such as bulk density, tapped density, 
angle of repose, compressibility index and Hausner ratio were determined and tabulated in 
Table No 14 After compression, evaluation tests of tablets such as general appearance, 
hardness, weight variation, friability, and content uniformity and other parameters such as in 
vitro drug release, IR analysis studies and stability studies were also preformed and the 
results are presented. 
 Drug-Polymer compatibility studies: 
  The physical and chemical state of polymers like HPMC K4M, Eudragit 100S, Guar 
gum and their admixture of polymer and drug used in Ciprofloxacin floating tablets prepared 
were studied by FTIR. 
FTIR studies: 
 The samples for FTIR Spectral analysis were shown in table no.5 and peaks were 
shown in figure 5 to 12 and the interpretation of FTIR spectrum of Ciprofloxacin Hcl intable 
8 .The physical mixture of drug and polymer was characterized by FTIR spectralanalysis for 
any physical as well as chemical alterations of drug characteristics. From theresult it was 
concluded that there was no interface of functional groups as principle peak ofCiprofloxacin 
Hydrochloride were found to be unaltered in the drug polymer physicalmixture. The physical 
parameters of drug as well as excipients concluded that there was nochange in peaks of 
admixture compared with drug whichindicates that the drug and excipients are compatible. 
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Fig 6: FTIR Spectrum of Ciprofloxacin Hcl 
 
 
Table -6: FTIR Spectrum of Ciprofloxacin Hydrochloride 
 
S.NO WAVE NUMBER (CM-) ASSIGNMENT   (Functional groups) 
1 1623.17 C=O carbonyl group 
2 1458.25 C-N Stretch 
3 3528.92 O-H Stretch 
4 3472.02 N-H Stretch 
5 2957.00 Aliphatic C-H Stretch 
6 2830.66 N-C Stretch 
7 1519.97 C=O Stretch of quinoline 
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Fig7: FTIR Spectrum of HPMC K4M 
 
Table-7:  FTIR Spectrum HPMC K4M 
S.No WAVE NUMBER (cm) ASSIGNMENT (Functional groups) 
1 3377.50 O-H Stretching 
2 2941.57 CH2 Stretching 
3 1588.45 C=C Stretching 
4 1460.18 Ar C-C Stretching 
5 1383.98 C-O Stretching 
6 946.12 O-H Bending 
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Fig 8: FTIR Spectrum of Eudragit 100S 
 
Table-8:  FTIR Spectrum of Eudragit 100S 
 
S.No WAVE NUMBER (cm) ASSIGNMENT (Functional groups) 
1 2957.97 C-H  Stretching 
2 1719.61 C=O Stretching 
3 1449.57 C=C Stretching 
4 986.63 C-O Stretching 
5 764.81 C-H Bending 
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Fig 9: FTIR Spectrum of Guar gum 
 
Table-9:  FTIR Spectrum Guar gum 
S.No WAVE NUMBER (cm) ASSIGNMENT (Functional groups) 
1 3393.90 O-H Stretching vibration 
2 2962.79 C-H Stretching of CH2 group 
4 1348.30, 1453.43 Symmetrical deformation of CH2 group 
5 1150.59, 1099.47 C-OH & primary alcohol; -CH2OH 
Stretching mode 
6 1048.36 -CH2 twisting vibration 
7 878.61 Galactose& Mannose 
8 799.53 
 
(1-4), (1-6) linkage of Galactose& Mannose 
respectively 
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Fig 10: FTIR Spectrum of Ciprofloxacin Hcl& HPMC K4M 
 
Table-10: FTIR Spectrum Ciprofloxacin Hcl& HPMC K4M 
S.No WAVE NUMBER (cm) ASSIGNMENT (Functional group) 
1 1590.38-1623.17 C=O Stretching 
2 1458.25 C-N Stretch 
3 3462.37-3528.92 O-H Stretch 
4 3462.37 N-H Stretch 
5 2819.09-2830.66 Aliphatic C-H Stretch 
6 1590.38 N-C Stretch 
7 1383.98 C-O Stretching 
8 947.09 O-H Bending 
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Discussion: 
 Ciprofloxacin Hcl contains functional groups like C=O (Carbonyl group), C-N 
(Cyanide group), O-H (Hydroxyl group), N-H (Amino group), Aliphatic C-H group, N-C 
(Isocyanide group) etc., which are not disturbed when combined Ciprofloxacin Hcl with 
HPMC K4M. It states that combination of Ciprofloxacin Hcl with HPMC K4M doesnot 
shows any interactions with functional groups present in Ciprofloxacin Hcl as well as HPMC 
K4M. So we can conclude that Ciprofloxacin Hcl and HPMC K4M are compatible with each 
other. 
 
 
Fig 11: FTIR Spectrum of Ciprofloxacin Hcl&Eudragit 100S 
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Table-11:  FTIR Spectrum Ciprofloxacin Hcl&Eudragit 100S 
 
S.No WAVE NUMBER (cm) ASSIGNMENT (Functional group) 
1 1733.12 C=O Stretching 
2 1449.57-1458.25 C-N Stretch 
3 3528.92-3642.73 O-H Stretch 
4 3472.02-3642.73 N-H Stretch 
5 2932.89-2957.00 Aliphatic C-H Stretch 
6 2818.12-2830.66 N-C Stretch 
7 1483.32-1519.97 C=O Stretch of quinoline 
 
Discussion: 
 Ciprofloxacin Hcl contains functional groups like C=O (Carbonyl group), C-
N(Cyanide group), O-H (Hydroxyl group), N-H (Amino group), Aliphatic C-H group, N-
C(Isocyanide group), C=O of quinolineetc., which are not disturbed when 
combinedCiprofloxacin Hcl with Eudragit 100S. It states that combination of 
CiprofloxacinHclwith Eudragit 100Sdoesnot shows any interactions with functional groups 
present inCiprofloxacin Hcl as well as Eudragit 100S. So we can conclude that Ciprofloxacin 
Hcland Eudragit 100S are compatible with each other. 
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Fig 12: FTIR Spectrum of Ciprofloxacin Hcl& Guar gum 
 
Table-12: FTIR Spectrum Ciprofloxacin Hcl& Guar gum 
S.No WAVE NUMBER (cm) ASSIGNMENT (Functional group) 
1 1627.99 C=O Stretching 
2 1460.18 C-N Stretch 
3 3370.75-3584.86 O-H Stretch 
4 3495.16 N-H Stretch 
5 2962.79 Aliphatic C-H Stretch 
6 2823.91 N-C Stretch 
7 1522.87 C=O Stretch of quinoline 
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Discussion: 
 Ciprofloxacin Hcl contains functional groups like C=O (Carbonyl group), C-
N(Cyanide group), O-H (Hydroxyl group), N-H (Amino group), Aliphatic C-H group, N-
C(Isocyanide group), C=O of quinoline etc., which are not disturbed when 
combinedCiprofloxacin Hcl with Guar gum. It states that combination of 
CiprofloxacinHclwith Guar gum doesnot shows any interactions with functional groups 
present in CiprofloxacinHcl as well as Guar gum. So we can conclude that Ciprofloxacin Hcl 
and Guar gumarecompatible with each other. 
 
 
Fig 13: FTIR Spectrum of Ciprofloxacin Hcl, HPMC K4M, Eudragit 100S, Guar gum, 
NAHCO3 & Citric acid 
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Table-13:  FTIR Spectrum Ciprofloxacin Hcl, HPMCK4M, Eudragit 100S, Guar gum, 
NaHCO3 & Citric acid 
 
S.No WAVE NUMBER (cm) ASSIGNMENT (Functional group) 
1 1598.09 C=O Stretching 
2 1447.64 C-N Stretch 
3 3578.11 O-H Stretch 
4 2818.12 Aliphatic C-H Stretch 
5 1581.70 C=C Stretching 
6 1385.91 C-O Stretching 
7 993.38 O-H Stretch 
8 1385.91-1447.64 Symmetrical deformation of CH2 group 
9 1084.04-1157 C-OH & primary alcohol; -CH2OH Stretching 
mode 
10 764.81 
 
(1-4), (1-6) linkage of Galactose& Mannose 
respectively 
 
Discussion: 
                Ciprofloxacin Hcl contains functional groups like C=O (Carbonyl group), C-
N(Cyanide group), O-H (Hydroxyl group), Aliphatic C-H group, N-C (Isocyanide group) etc 
which are not disturbed when combined Ciprofloxacin Hcl with HPMC K4M, Eudragit 100S 
and Guar gum. It states that combination of Ciprofloxacin Hcl with HPMC 
K4M,Eudragit100S and Guar gum doesnot shows any interactions with functional groups 
present inCiprofloxacin Hcl as well as HPMC K4M, Eudragit 100S and guar gum. So we can 
conclude that Ciprofloxacin Hcl, HPMC K4M, Eudragit100S and Guar gum are compatible 
with each other. 
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Preformulation studies of granules of Ciprofloxacin Hcl floating tablets 
 The granules of CiprofloxainHcl floating tablets were prepared by wet granulation 
technique. The prepared granules are subjected to preformulation studies by following 
methods. 
Angle of repose: 
 The granules of all seven formulations are subjected to angle of repose by funnel 
method. The value of angle of repose was found in the range of 22º71′-26º15′. The result 
proved that the granules of all formulations showed excellent flow properties. 
Bulk density: 
 Bulk density of all the granules was measured by using measuring cylindermethod 
and the resultant values was found in the range of 0.37-0.85 g/cm. It showed that the 
bulkiness is within the acceptable limits. 
Tapped density: 
 The tapped density of all granules was determined by tapping the Measuring cylinder 
for required times and the values are were noted in tableand the tapped density values was 
found in the range of 0.42-0.49 g/cm. The result proven that the tapped density values are 
within the acceptable limits. 
Compressibility index: 
 The compressibility of granules are done by tapped density minus bulk density and 
divided with tapped density values. And the resultant values is in the range of 9-15. It 
indicates that the granules showed good flow properties. 
 Hausner’s ratio:It is the ratio of tapped density value to bulk density value and the 
resultant values of Hausner’s ratio of all the formulations is between  1.10-1.18 which 
indicate that the granules  shows good flow. 
 
 
 
70 
 
Table No-14: Evaluation of granules of Ciprofloxacin Hcl floating tablets 
 
S. No 
Formulation 
code 
Angle of 
response 
Bulk 
density 
(gm/ml) 
Tapped 
density 
(gm/ml) 
Compressibility    
index (%) 
Hausner’s  
ratio 
1 F1 22º71′ 0.42 0.49 11.22 1.166 
2 F2 22º91´ 0.386 0.435 11.34 1.126 
3 F3 24º52´ 0.393 0.436 9.86 1.1 
4 F4 24º01′ 0.375 0.429 12.59 1.14 
5 F5 25º17´ 0.3707 0.417 11.16 1.13 
6 F6 26º15´ 0.40 0.448 10.714 1.1 
7 F7 24º92´ 0.85 0.455 15.39 1.18 
 
 Characterization of Ciprofloxacin Hcl floating tablets 
General appearance:  
 The formulated tablets were evaluated for organoleptic charactes. The tablets are 
circular in shape, yellowish in colour, with no characteristic odour. All tablets showed 
elegance in appearance. 
Hardness test: 
  The hardness of Ciprofloxacin Hcl floating tablets were measured by Pfizer hardness 
tester and the values were tabulated in table. The hardness of all tablets in all formulations 
was within the range of 4.5-5.1 kg/cm². So all formulated tablets passes the test. 
Friability test: 
 The friability of Ciprofloxacin Hcl floating tablets were performed by using Roche 
friabilator and thethe friability of all formulated tablets was within 1%. It proedthat all 
formulations are within the acceptable limits. 
\ 
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Diameter: 
 The diameter of Ciprofloxacin Hcl floating tablets were measured by using 
BestoVernier calipers and there is no deviation in the diameter values of all formulated 
tablets indicates uniform diameter. 
Thickness: 
 The thickness of Ciprofloxacin Hcl floating tablets were measured by using Vernier 
calipers. Thickness must be controlled to facilitate packaging. The result showed that the 
tablets of all the formulations shows uniform thickness. 
 
Table 15: Evaluation of Ciprofloxacin Hcl floating tablets 
S. No. Formulation 
code Hardness(kg) 
Friability 
(%) 
Thickness 
(mm) 
Diameter 
(mm) 
1 F1 4.85 0.631 4.17 10.19 
2 F2 4.8 0.413 5.14 10.8 
3 F3 5.1 0.462 5.16 11.0 
4 F4 4.75 0.381 4.4 10.7 
5 F5 4.5 0.54 4.16 10.9 
6 F6 5.0 0.761 4.5 11.0 
7 F7 4.8 0.62 4.2 10.8 
 
Weight variation test: 
 The weight variation of tablets were done by weighing the individual tablet weight 
and the average weight of 20 tablets which were selected randomly from each formulation 
batches. No more than two tablets should go more than the preferred deviation. The 
percentage deviation is 7.5% for more than 130 mg tablets and here actual weight of tablet is 
500 mg. So the acceptable deviation was 7.5%, thus all formulation passes the test. 
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Drug content (%): 
  The percentage of drug content were done by dissolving individual tablet in 0.1N Hcl 
and transferred to a 100ml volumetric flask. The absorbance of the resulting solution is 
measured by Ultraviolet  Spectroscopy at 278nm. As per IP, the content uniformity should be 
in the range of 90-110%. The result showed that the percentage of Ciprofloxacin Hcl in all 
formulations was ranging from 96-99%. It released that the drug is uniformly dispersed in 
the formulation and confirms the homogeneous mixing of the drug and the polymer. So all 
the formulated tablets passes the test. 
 
Table 16: Weigh variation and Estimation of Drug content of floating tablets 
S. No Formulation code Weight variation Drug content (%) 
1 F1 498±2.5 98.12 
2 F2 496±3.2 97.23 
3 F3 497±2.7 98.63 
4 F4 499±1.13 99.54 
5 F5 498±3.5 97.83 
6 F6 495±4.3 97.38 
7 F7 497±4.2 99.17 
 
Buoyancy lag time: 
 It is the time taken during which of dosage form remains buoyant on 0.1N Hcl were 
measured and the values were listed in table. The buoyancy lag time values were found in the 
range of 134-166 sec. 
Total floating time:  
 It is the total duration of time during which the dosage form remains buoyant is 
measured and the values were ranges between 356-485 min which was noted in table.  
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Table 17: Floating Lag time and floating time of formulations 
S.No Formulation code Floating Lag Time 
(Sec) 
Floating Time 
(hours) 
1 F1 150 10.0 
2 F2 144 10.5 
3 F3 151 8.0 
4 F4 134 12.5 
5 F5 154 9.0 
6 F6 166 9.5 
7 F7 140 11.0 
 
 
 
 At Initial Time: o sec                                      At Floating Time: 2 mins 46 secs 
 
Fig 14: Floating Studies for Optimized formulation (F4): (Ciprofloxacin Hcl + HPMC 
K4M+ Eudragit 100S) 
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 In-vitro dissolution studies: 
 The in-vitro dissolution studies of all seven formulation of Ciprofloxacin floating 
tablets were shown in following tables no 18-25and figure 15-22 
 The percentage drug release of all formulations after 12 hours using HPMC  K4M, 
Eudragit 100Sand guar gum was found to be 88.12% (F1), 90.68% (F2) and 73.45% (F3) 
repectively. And the percentage drug release of combination of HPMC K4M with Eudragit 
100S is 98.87% (F4), Eudragit 100S with guar gum is 85.67% (F5),HPMC K4M with guar 
gum is 79.93% (F6) and HPMC K4M with Eudragit 100S and guar gum is 95.45% (F7). 
 From the in-vitro drug release, it was observes that the maximum drug release was 
found in formulation F4 is 98.87%. It shows that F4 formulation exhibits optimized drug 
release when compared with other formulation. The dissolution profile of all formulations of 
Ciprofloxacin Hcl floating tablets were shown in following table no 18-25 
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Table-18: Dissolution profile of Formulation  (F1): 
(Ciprofloxacin Hcl + HPMC K4M) 
S.No 
 
Time 
(hrs) 
Absorbance 
(278nm) 
Concentration 
(µg/ml) 
Amount of 
drug release 
Percentage of 
drug release 
(%) 
1 1 0.094 1.740 0.224 11.22 
2 2 0.117 2.166 0.279 14.3 
3 3 0.162 3.00 0.387 19.8 
4 4 0.221 4.092 0.527 27.01 
5 5 0.276 5.111 0.659 33.73 
6 6 0.326 6.037 0.778 39.84 
7 7 0.387 7.166 0.924 47.3 
8 8 0.434 8.037 1.036 53.04 
9 9 0.523 9.685 1.249 63.92 
10 10 0.589 10.907 1.407 71.98 
11 11 0.653 12.092 1.559 79.81 
12 12 0.721 13.351 1.722 88.12 
 
 
Fig 15: Dissolution profile of Formulation  (F1): 
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Table no-19:Dissolution profile of Formulation (F2): 
(Ciprofloxacin Hcl + Eudragit 100S) 
S,No Time (hrs) 
Absorbance 
(278nm) 
Concentration 
(µg/ml) 
Amount of 
drug release 
Percentage of 
drug release 
(%) 
1 1 0.079 1.462 0.188 9.43 
2 2 0.132 2.444 0.315 16.13 
3 3 0.176 3.259 0.42 21.51 
4 4 0.245 4.537 0.585 29.94 
5 5 0.294 5.444 0.702 35.93 
6 6 0.342 6.330 0.817 41.8 
7 7 0.411 7.611 0.981 50.23 
8 8 0.476 8.814 0.137 58.17 
9 9 0.562 10.407 0.342 68.68 
10 10 0.616 11.400 0.471 75.28 
11 11 0.672 12.440 0.605 82.13 
12 12 0.742 13.74 0.772 90.68 
 
 
Fig 16: Dissolution profile of Formulation  (F2): 
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Table-20: Dissolution profile of Formulation  (F3): 
(Ciprofloxacin Hcl + Guar gum) 
S,No Time 
(hrs) 
Absorbance 
(278nm) 
Concentration 
(µg/ml) 
Amount of 
drug release  
Percentage of 
drug release (%) 
1 1 0.069 1.277 0.164 8.24 
2 2 0.085 1.574 0.203 10.38 
3 3 0.112 2.074 0.267 13.68 
4 4 0.153 2.833 0.365 18.7 
5 5 0.21 3.88 0.501 25.66 
6 6 0.247 4.574 0.590 30.18 
7 7 0.297 5.500 0.709 36.3 
8 8 0.344 6.37 0.821 42.04 
9 9 0.421 7.796 1.005 51.45 
10 10 0.473 8.759 1.129 57.81 
11 11 0.572 10.592 1.366 69.91 
12 12 0.601 11.129 1.435 73.45 
 
 
 
Fig 17: Dissolution profile of Formulation  (F3): 
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Table-21: Dissolution profile of Formulation  (F4): 
(Ciprofloxacin Hcl + Eudragit 100S+ HPMC K4M) 
S,No Time 
(hrs) 
Absorbance 
(278nm) 
Concentration 
(µg/ml) 
Amount of 
drug release  
Percentage of 
drug release (%) 
1 1 0.102 1.88 0.243 12.18 
2 2 0.171 1.166 0.408 20.9 
3 3 0.222 4.111 0.53 27.13 
4 4 0.301 5.574 0.719 36.78 
5 5 0.36 6.667 0.86 44 
6 6 0.429 7.944 1.024 52.43 
7 7 0.497 9.203 1.187 60.74 
8 8 0.565 10.463 1.349 69.05 
9 9 0.632 11.703 1.509 77.24 
10 10 0.699 12.944 1.66 85.43 
11 11 0.752 13.925 1.79 91.91 
12 12 0.809 14.98 1.93 98.87 
 
 
                               Fig 18: Dissolution profile of Formulation 4 (F4): 
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Table-22: Dissolution profile of Formulation  (F5): 
(Ciprofloxacin Hcl +Eudragit 100S+ Guar gum) 
S,No Time (hrs) 
Absorbance 
(278nm) 
Concentration 
(µg/ml) 
Amount of 
drug release 
Percentage of drug 
release (%) 
1 1 0.083 1.537 0.198 9.91 
2 2 0.105 1.944 0.25 12.83 
3 3 0.138 2.55 0.329 16.86 
4 4 0.198 3.66 0.473 24.2 
5 5 0.255 4.722 0.609 31.16 
6 6 0.306 5.67 0.731 37.4 
7 7 0.342 6.33 0.817 41.8 
8 8 0.411 7.611 0.98 50.23 
9 9 0.482 8.925 1.51 58.91 
10 10 0.557 10.314 1.33 68.07 
11 11 0.623 11.537 1.488 76.14 
12 12 0.701 12.98 1.674 85.67 
 
 
Fig 19: Dissolution profile of Formulation  (F5): 
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(Ciprofloxacin Hcl+ HPMC K4M+ Guar gum) 
S,No Time (hrs) 
Absorbance 
(278nm) 
Concentration 
(µg/ml) 
Amount of 
drug release 
Percentage of 
drug release (%) 
1 1 0.088 1.629 0.210 10.51 
2 2 0.100 1.851 0.238 12.22 
3 3 0.125 2.314 0.298 15.27 
4 4 0.175 3.24 0.418 21.38 
5 5 0.244 4.518 0.582 29.82 
6 6 0.296 5.48 0.707 36.17 
7 7 0.335 6.203 0.80 40.94 
8 8 0.394 7.296 0.941 48.15 
9 9 0.442 8.19 1.055 54.02 
10 10 0.512 9.481 1.223 62.57 
11 11 0.593 10.981 1.416 72.47 
12 12 0.654 12.11 1.562 79.93 
 
 
Fig 20: Dissolution profile of Formulation  (F6): 
 
Table -24: Dissolution profile of Formulation (F7): 
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(Ciprofloxacin Hcl+HPMC K4M+ Eudragit 100S+ Guar gum) 
S,No Time (hrs) 
Absorbance 
(278nm) 
Concentration 
(µg/ml) 
Amount of 
drug release 
Percentage of drug 
release (%) 
1 1 0.092 1.703 0.219 10.98 
2 2 0.156 2.889 0.372 19.06 
3 3 0.203 3.759 0.484 24.81 
4 4 0.254 4.703 0.606 31.04 
5 5 0.321 5.944 0.766 39.23 
6 6 0.373 6.907 0.891 45.58 
7 7 0.418 7.740 0.998 51.08 
8 8 0.503 9.314 1.201 61.47 
9 9 0.577 10.685 1.378 70.52 
10 10 0.668 12.370 1.595 81.64 
11 11 0.712 13.185 1.70 87.02 
12 12 0.781 14.463 1.865 95.45 
 
 
                            Fig 21: Dissolution profile of Formulation (F7): 
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Table-25:Comparitive In-vitro Dissolution study of Ciprofloxacin Hcl floating tablets 
(F1-F7) 
 
Time (hrs) Cumulative % Drug Release 
 F1 F2 F3 F4 F5 F6 F7 
1 11.22 9.43 8.24 12.18 9.91 10.51 10.98 
2 14.3 16.13 10.38 20.9 12.83 12.22 19.06 
3 19.8 21.51 13.68 27.13 16.86 15.27 24.81 
4 27.01 29.94 18.7 36.78 24.2 21.38 31.04 
5 33.73 35.93 25.66 44 31.16 29.82 39.23 
6 39.84 41.8 30.18 52.43 37.4 36.17 45.58 
7 47.3 50.23 36.3 60.74 41.8 40.94 51.08 
8 53.04 58.17 42.04 69.05 50.23 48.15 61.47 
9 63.92 68.68 51.45 77.24 58.91 54.02 70.52 
10 71.98 75.28 57.81 85.43 68.07 62.57 81.64 
11 79.81 82.13 69.91 91.91 76.14 72.47 87.02 
12 88.12 90.68 73.45 98.87 85.67 79.93 95.45 
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Fig 22: Comparitive In-vitro Dissolution study of Ciprofloxacin Hcl floating tablets    
(F1-F7) 
Kinetic Analysis of dissolution data: 
 To know the mechanism of drug release from these formulations, the data were 
treated according to zero order72,first order73, Higuchi’s model75and Korsmeyermodel76 The 
release rate kinetic data for all the formulations are shown in table. When data were  
plottedaccording to zero order, the formulation showed high linearity with regression  co-
efficient values (R2) between0.993 – 0.998. 
 Diffusion is related to transport of drug from the dosage matrix into the invitrostudy 
fluid depending on the concentrations. This is explained by Higuchi’s equations, as the plot 
showed high linearity with regression co-efficient values (R2) between 0.878- 0.938.         
 By using Korsmeyer model, if n= 0.45, it is Fickiandiffusion , if n= 0.45-0.89 it is 
non-Fickian transport. Here all the formulations showed ‘n’ values between0.806-0.929. So 
all the formulations follows non- Fickian diffusion transport mechanism. Finally all the 
formulations follows the mechanism of both diffusion and erosion.       
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Table 26-: Kinetic Analysis of dissolution data: 
 
 
S.No 
Formulation 
code 
Regression co-efficient (R2) Korsmeyer’ plot 
Zero order 
plot 
First order 
plot 
Higuchi’s 
plot 
R2 Slope (n) 
1 F1 0.993 0.886 0.896 0.970 0.887 
2 F2 0.997 0.889 0.910 0.993 0.929 
3 F3 0.988 0.880 0.878 0.997 0.868 
4 F4 0.998 0.763 0.938 0.996 0.861 
5 F5 0.988 0.880 0.878 0.998 0.806 
6 F6 0.988 0.880 0.878 0.998 0.825 
7 F7 0.995 0.832 0.912 0.990 0.877 
 
 
 
 
 
 
 
 
 
Fig 23: Release Kinetics for Optimized Formulation (F4): 
(Ciprofloxacin Hcl + Eudragit 100S+ HPMC K4M) 
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Percentage Release of Innovator Sample (Cipro XR 500mg) & Prepared Formulation of 
Ciprofloxacin Hcl floating tablets 
Table No -27 
 
S.No 
 
Time (hrs) 
Cumulative percentage drug release 
Innovator 
sample 
Optimized formulation of 
Ciprofloxacin Hcl (F4) 
1 1 10.23 12.18 
2 2 16.57 20.90 
3 3 24.06 27.13 
4 4 31.85 36.78 
5 5 38.92 44.00 
6 6 47.73 52.43 
7 7 55.81 60.74 
8 8 62.34 69.05 
9 9 70.71 77.24 
10 10 79.11 85.43 
11 11 88.19 91.91 
12 12 95.61 98.87 
 
 
 
 
 
 
 
 
88 
 
 
Fig 24: Percentage Release of Innovator Sample (Cipro XR 500mg) & Ciprofloxacin Hcl 
floating tablets 
STABILITY STUDIES 
 Ciprofloxacin floating  tablets (all 7 formulations) were stored at refrigerated 
temperature (4C ± 2C), room temperature (27C± 2C) and in programmable envirnomental 
test chamber (45C± 2C) for 45 days. 
 At the end of 15, 30 and 45 days of storage, the floating tablets were observed for 
changes in physical appearance analyzed for drug content and subjected to invitro release 
studies and the result was presented in Table no 28-35 
 There was no change in the percentage release of ciprofloxacin    from all the 
formulations stored at different temperatures upto 45 days. Tablet evaluation tests were 
carried out and there were no deviations in all the tests and all are within the limits. It showed 
that all the formulations are physically stable. There was no change in the drug content (Table 
no 28 and invitro drug release (Table no 29-35). It showed that all the formulations are 
chemically stable. 
0
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Table No – 28 
 
DRUG CONTENT ESTIMATION AFTER STORING AT DIFFERENT TEMPERATURES 
 
No 
Fo
rm
u
la
tio
n 
 
Drug content* 
40C 20C 270C 20C 450C 20C 
15th days 30th days 45th days 15th days 30th days 45th days 15th days 30th days 45th days 
1 F1 98.12 98.10 98.11 98.62 98.60 98.60 98.98 98.99 98.99 
2 F2 97.73 97.73 97.72 97.20 97.20 97.21 97.43 97.43 97.41 
3 F3 98.63 98.64 98.65 98.69 98.69 98.68 98.63 98.64 98.63 
4 F4 99.64 99.64 99.63 99.44 99.44 99.45 99.54 99.53 99.54 
5 F5 97.80 97.81 97.80 97.87 97.86 97.86 97.68 97.67 97.68 
6 F6 97.45 97.47 97.45 97.98 97.97 97.97 97.78 97.79 97.78 
7 F7 99.67 99.67 99.68 99.17 99.18 99.17 99.10 99.10 99.11 
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Table No – 29 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION F1 
 
S.
N
o 
Ti
m
e i
n 
(h
rs
) 
0 days 
Percentage drug release (%)*  
15th days 30th days 45th days 
40C± 20C 
270C ± 
20C 
450C± 
20C 
40 C± 20C 270C± 20 C 450C± 20C 40C± 20C 
270C±  
20 C 
450C± 
20C 
1 1 11.22 11.20 11.82 11.02 11.22 11.44 11.21 11.25 11.88 11.22 
2 2 14.3 14.36 14.39 14.33 14.55 14.39 14.31 14.39 14.90 14.54 
3 3 19.8 19.45 19.84 19.85 19.89 19.98 19.43 19.86 19.77 19.89 
4 4 27.01 26.31 27.09 27.45 27.00 27.08 27.66 27.01 27.66 27.96 
5 5 33.73 33.73 33.03 33.73 33.79 33.66 33.79 33.88 33.79 33.70 
6 6 39.84 40.24 39.24 39.89 39.76 39.80 39.83 39.80 39.84 39.53 
7 7 47.31 47.98 47.31 47.35 47.21 47.34 47.39 47.77 47.36 47.73 
8 8 53.04 53.64 53.00 53.44 53.99 53.00 53.32 53.00 53.09 53.84 
9 9 63.92 63.09 63.95 63.90 63.09 63.66 63.85 63.93 63.92 63.34 
10 10 71.98 70.56 71.99 71.33 71.21 71.32 71.90 71.66 71.84 71.74 
11 11 79.81 79.96 79.31 79.80 79.80 79.98 79.56 79.95 79.81 79.81 
12 12 88.12 88.10 88.56 88.46 88.16 88.54 88.87 88.13 88.09 88.19 
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Table No – 30 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION F2 
 
 
 
S.
N
o 
Ti
m
e i
n 
(h
rs
) 
0 days 
Percentage drug release (%)*  
15th days 30th days 45th days 
40C± 20C 
270C ± 
20C 
450C± 
20C 
40 C± 20C 270C± 20 C 450C± 20C 40C± 20C 
270C±  
20 C 
450C± 
20C 
1 1 9.43 9.53 9.99 9.22 9.78 9.21 9.43 8.43 9.54 9.93 
2 2 16.13 16.03 16.55 16.18 16.07 16.63 16.10 16.53 16.10 16.53 
3 3 21.51 22.58 21.50 21.66 20.57 21.74 21.22 21.89 21.57 21.65 
4 4 29.94 29.89 30.90 29.32 29.93 29.97 28.97 29.96 29.90 30.94 
5 5 35.93 35.98 35.55 35.23 35.74 35.93 35.55 35.90 35.84 35.91 
6 6 41.8 42.80 41.76 41.87 41.88 41.67 41.60 42.76 41.80 41.11 
7 7 50.23 50.27 50.32 50.37 51.44 50.24 50.23 50.98 51.85 50.53 
8 8 58.17 58.97 57.17 58.10 58.17 58.17 58.18 58.81 58.91 58.97 
9 9 68.68 69.55 68.69 68.63 68.69 68.63 67.86 69.67 70.44 67.58 
10 10 75.28 75.27 75.52 75.44 75.82 75.67 75.98 75.82 75.33 75.54 
11 11 82.13 82.22 83.10 82.24 82.31 82.94 82.63 82.13 82.74 82.56 
12 12 90.68 90.66 90.60 90.67 91.76 90.65 90.60 90.68 90.70 90.68 
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Table No – 31 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION F3 
 
 
S.
N
o 
Ti
m
e i
n 
(h
rs
) 
0 days 
Percentage drug release (%)*  
15th days 30th days 45th days 
40C± 20C 
270C ± 
20C 
450C± 
20C 
40 C± 20C 
270C±  
20 C 
450C± 20C 40C± 20C 
270C±  
20 C 
450C± 
20C 
1 1 8.24 8.23 8.25 8.24 8.23 8.22 8.23 8.24 8.21 8.24 
2 2 10.38 10.39 10.37 10.36 10.35 10.37 10.38 10.39 10.37 10.36 
3 3 13.68 13.66 13.65 13.67 13.69 13.68 13.68 13.67 13.67 13.66 
4 4 18.07 18.05 18.08 18.06 18.05 18.09 18.07 18.05 18.06 18.07 
5 5 25.66 25.65 25.64 25.65 25.66 25.63 25.66 25.64 25.65 25.61 
6 6 30.18 30.19 30.17 30.18 30.19 30.16 30.18 30.17 30.19 30.17 
7 7 36.03 36.01 36.02 36.04 36.01 36.03 36.03 36.02 36.05 36.04 
8 8 42.04 42.03 42.00 42.01 42.05 42.04 42.04 42.05 42.02 42.03 
9 9 51.45 51.46 51.44 51.47 51.46 51.44 51.45 51.46 51.46 51.44 
10 10 57.81 57.82 57.80 57.83 57.80 57.82 57.81 57.83 57.80 57.82 
11 11 69.91 69.90 69.89 69.92 69.91 69.92 69.91 69.93 69.92 69.94 
12 12 73.45 73.44 73.43 73.42 73.41 73.43 73.45 73.44 73.44 73.46 
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Table No – 32 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION F4 
 
S.
N
o 
Ti
m
e i
n 
(h
rs
) 
0 days 
Percentage drug release (%)*  
15th days 30th days 45th days 
40C± 20C 
270C ± 
20C 
450C± 
20C 
40 C± 20C 270C± 20 C 450C± 20C 40C± 20C 
270C±  
20 C 
450C± 
20C 
1 1 12.18 12.17 12.15 12.16 12.15 12.19 12.17 12.16 12.15 12.19 
2 2 20.09 20.08 20.07 20.10 20.08 20.09 20.10 20.08 20.07 20.06 
3 3 27.13 27.14 27.12 27.11 27.12 27.15 27.11 27.14 27.12 27.14 
4 4 36.78 36.76 36.77 36.79 36.78 36.75 36.76 36.77 36.76 36.78 
5 5 44 44.02 44.01 44.03 44 44.04 44.01 44.04 44.01 44 
6 6 52.43 52.44 52.42 52.45 52.44 52.42 52.45 52.44 52.45 52.42 
7 7 60.74 60.72 60.73 60.71 60.75 60.71 60.73 60.74 60.70 60.73 
8 8 69.05 69.06 69.04 69.02 69.07 69.08 69.06 69.05 69.08 69.02 
9 9 77.24 77.25 77.23 77.22 77.25 77.24 77.26 77.23 77.25 77.21 
10 10 85.43 85.42 85.44 85.45 85.42 85.41 85.42 85.44 85.41 85.42 
11 11 91.91 91.93 91.92 91.90 91.89 91.90 91.93 91.90 91.92 91.94 
12 12 98.87 98.86 98.88 98.85 98.84 98.86 98.85 98.84 98.85 98.86 
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Table No – 33 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION F5 
S.
N
o 
Ti
m
e 
in
 (h
rs
) 
0 days 
Percentage drug release (%)*  
15th days 30th days 45th days 
40C± 
20C 
270C ± 
20C 
450C± 
20C 
40 C± 
20C 
270C±  
20 C 
450C± 
20C 
40C± 
20C 
270C±  
20 C 
450C± 
20C 
1 1 9.91 9.92 9.93 9.90 9.94 9.95 9.94 9.91 9.92 9.93 
2 2 12.83 12.82 12.84 12.82 12.80 12.83 12.82 12.84 12.85 12.80 
3 3 16.86 16.87 16.85 16.84 16.87 16.84 16.87 16.85 16.86 16.87 
4 4 24.02 24.02 24.01 24.03 24.04 24.02 24.01 24.00 24.01 24.02 
5 5 31.16 31.17 31.15 31.14 31.13 31.14 31.17 31.18 31.15 31.13 
6 6 37.04 37.04 37.03 37.00 37.01 37.05 37.07 37.06 37.01 37.02 
7 7 41.08 41.07 41.06 41.05 41.02 41.04 41.05 41.08 41.07 41.06 
8 8 50.23 50.22 50.25 50.21 50.22 50.21 50.20 50.22 50.25 50.24 
9 9 58.91 58.93 58.92 58.90 58.91 58.92 58.94 58.90 58.92 58.90 
10 10 68.07 68.08 68.06 68.09 68.09 68.06 68.06 68.05 68.07 68.08 
11 11 76.14 76.12 76.11 76.13 76.15 76.11 76.13 76.15 76.12 76.13 
12 12 85.67 85.68 85.69 85.66 85.65 85.67 85.65 85.66 85.64 85.66 
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Table no – 34 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION F6 
 
S.
N
o 
Ti
m
e i
n 
(h
rs
) 
0 days 
Percentage drug release (%)*  
15th days 30th days 45th days 
40C± 20C 
270C ± 
20C 
450C± 
20C 
40 C± 20C 
270C±  
20 C 
450C± 20C 40C± 20C 
270C±  
20 C 
450C± 
20C 
1 1 10.51 10.50 10.52 10.53 10.54 10.51 10.50 10.53 10.52 10.51 
2 2 12.22 12.20 12.21 12.23 12.24 12.25 12.22 12.20 12.21 12.23 
3 3 15.27 15.26 15.28 15.25 15.26 15.23 15.24 15.25 15.27 15.29 
4 4 21.38 21.35 21.36 21.39 21.38 21.37 21.35 21.36 21.37 21.39 
5 5 29.82 29.80 29.81 29.83 29.84 29.85 29.84 29.82 29.81 29.80 
6 6 36.17 36.16 36.19 36.18 36.18 36.12 36.13 36.15 36.16 36.15 
7 7 40.94 40.93 40.95 40.91 40.92 40.93 40.96 40.94 40.95 40.93 
8 8 48.15 48.16 48.17 48.18 48.14 48.11 48.13 48.12 48.15 48.11 
9 9 54.02 54.03 54.01 54.02 54.05 54.04 54.01 54.02 54.03 54.00 
10 10 62.57 62.56 62.55 62.57 62.58 62.59 62.60 62.58 62.56 62.55 
11 11 72.47 72.45 72.46 72.44 72.43 72.42 72.45 72.48 72.46 72.48 
12 12 79.93 79.92 79.90 79.92 79.91 79.91 79.94 79.96 79.95 79.93 
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Table No – 35 
STABILITY STUDIES OF DISSOLUTION PROFILE OF FORMULATION F7 
S.
N
o 
Ti
m
e i
n 
(h
rs
) 
0 days 
Percentage drug release (%)*  
15th days 30th days 45th days 
40C± 20C 
270C ± 
20C 
450C± 
20C 
40 C± 20C 
270C±  
20 C 
450C± 20C 40C± 20C 
270C±  
20 C 
450C± 
20C 
1 1 10.98 10.96 10.97 10.98 10.95 10.94 10.92 10.91 10.98 10.94 
2 2 19.06 19.02 19.08 19.07 19.05 19.08 19.07 19.05 19.03 19.05 
3 3 24.81 24.83 24.82 24.84 24.80 24.78 24.79 24.82 24.81 24.80 
4 4 31.04 31.05 31.06 31.03 31.04 31.05 31.00 31.01 31.02 31.02 
5 5 39.23 39.24 39.26 39.25 39.24 39.27 39.21 39.20 39.26 39.23 
6 6 45.58 45.57 45.56 45.57 45.59 45.55 45.53 45.54 45.56 45.57 
7 7 51.08 51.06 51.07 51.04 51.06 51.05 51.06 51.09 51.07 51.06 
8 8 61.47 61.49 61.48 61.46 61.47 61.45 61.49 61.48 61.44 61.46 
9 9 70.52 70.51 70.53 70.54 70.52 70.50 70.49 70.51 70.52 70.53 
10 10 81.64 81.63 81.61 81.62 81.63 81.65 81.67 81.66 81.65 81.63 
11 11 87.02 87.00 87.01 87.04 87.06 87.00 87.03 87.04 87.03 87.05 
12 12 95.45 95.42 95.43 95.41 95.42 95.44 95.43 95.46 95.44 95.46 
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IX . SUMMARY AND CONCLUSION 
 
 Hydrodynamically balanced tablets of Ciprofloxacin Hcl can be formulated with an 
approach to increase gastric residence and thereby improves drug bioavailability to the 
developed floating tablets of Ciprofloxacin Hcl using natural and synthetic polymer HPMC 
K4M, Eudragit 100S and guar gum with Sodium bicarbonate combination and citric acid as 
gas generating agent was  prepared by wet granulation technique (F1- F7) was achieved.  
 
 Preformulation studies for drug such as angle of repose, bulk density, tapped density, 
compressibility index, Hausner’s ratio were performed and the result showed that all 
the parameters are within the limits 
 
 Tablets were prepared by wet granulation method and evaluated for 
generalappearance, hardness test, friability test, uniformity in weight, drug content 
estimation. All the formulations were found to be good appearance without showing 
any chipping, capping  and sticking defects and other parameters were also passedthe 
test. 
 
 FTIR Spectroscopic studies indicated that the drug is compatible with all excipients 
and there is no drug- polymer interactions. 
 
 When comparing all formulation F4  showed optimized drug release of  98.86% at 
the end of 12 hours. 
 
 These optimized F4 formulation showed buoyancy lag time of 134 sec. and floating 
time of.12.5 hrs respectively. 
 
 Data obtained from kinetic treatment revealed F4 formulations follow Koresmayer-
peppas model. The ‘n’ value is 0.861 indicates the non Fickian diffusion. 
 
 From the comparative study of optimized formulation of Ciprofloxacin Hcl (F4) with 
marketed product (Cipro XR 500mg) shows that F4 is have greater release than 
marketed product 
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 All the formulations were subjected for stability studies for 45 days at different 
temperatures such as room temperature, fridge temperature and acclerated 
temperature (45C2C). At 15 days interval upto 45 days, the drug content and 
dissolution studies were carried out. There was no significant change in the drug 
content and invitro drug release 
 
  From the above study, it was concluded that Ciprofloxacin Hcl can formulated as 
Floating drug delivery system which helps to increase gastric residence timethere by it 
increases the bioavailability and half life of Ciprofloxacin Hcl. 
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